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INTRODUCTION. SOFT TISSUE TUMORS: AN OVERVIEW AND OUTLINE OF THE THESIS
Soft tissue tumors are a highly heterogeneous group of tumors that are classified on 
a histogenetic basis according to the normal tissue they resemble.1 This principle has 
been the basis of histopathological classifications published by pathologists with 
Arthur Purdy Stout being one of the most famous pioneers. He wrote the first AFIP 
Fascicle on soft tissue tumors in 1957.2
 Soft tissue tumors are divided into a benign, intermediate and a malignant group. 
Most of the benign tumors more closely resemble normal tissue and have a limited 
capacity for autonomous growth, infiltration of adjacent structures and local recurrence 
following simple excision.1 In contrast, malignant tumors, sarcomas, are locally aggressive 
tumors with a high tendency for recurrence and metastases.3 They show varying 
resemblance to normal cell types, depending on their degree of differentiation. 
 Tumors of  the intermediate group behave locally aggressive, but rarely metastasize.4 
 Finally, it should be noted that not all mesenchymal tumor types are classifiable 
on basis of a presumed line of differentiation from normal mesenchymal tissue such 
as ossifying fibromyxoid tumor, synovial sarcoma, epithelioid sarcoma, and alveolar 
soft part sarcoma, which have no normal cell counterpart.1,4 
Classification 
The most widely accepted classification is the WHO Classification of Tumours of Soft 
Tissue and Bone, of which the first edition, published in 1969 by Enzinger, included 
only soft tissue tumors while the current edition, published in 2013 by a large 
international team  of pathologists, geneticists and medical oncologists, also includes 
lesions from bone.4,5 This classification provides uniform and hence reproducible 
diagnostic criteria, which enables a more consistent approach to diagnosis, prediction 
of biological behavior as well as treatment. Furthermore, now that tumors are 
classified in a more consistent fashion, it will be easier to understand their intrinsic 
biology through identifying specific and consistent genetic aberrations.5 
 The WHO classification distinguishes between histogenetically defined groups: 
adipocytic tumors, (myo)fibroblastic tumors, fibrohistiocytic tumors, smooth muscle 
tumors, skeletal muscle tumors, pericytic tumors, vascular tumors, chondrosseous 
tumors, gastrointestinal stromal tumors, and nerve sheath tumors. Tumors without a 
normal cell-counterpart are subsumed in the group of tumors with uncertain differ-
entiation.4
Histogenesis 
Mesenchymal stem cells or multipotential precursor cells are self-renewing cells that 
can give rise to mesodermally derived tissues including fat, muscle, endothelium, 
connective tissue, tendon, bone, cartilage and stromal cells.6,7
 According to the current understanding, most mesenchymal tumors are derived 
from these cells that are preprogrammed to differentiate into various mature cell 
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Several of the genetic alterations are of diagnostic and prognostic value, and the 
importance of molecular testing for guiding targeted therapeutic strategies in 
mesenchymal neoplasms is emerging.1,11 In this approach, refered to as precision medicine, 
the goal is to develop cancer drugs matching specific molecular characteristics of a 
tumor, ultimately leading to: “The right drug, the right dose, for the right patient, at 
the right time”.12
 The aim of this thesis is to analyze specific genetic alterations in benign and 
malignant soft tissue tumors contributing to classification and improvement of 
diagnoses, especially in entities with overlapping features.
Outline of the thesis
In chapter two, we investigated EWSR1 gene rearrangement in cutaneous myoepithelial 
tumors in order to compare them with their counterpart of soft tissue. 
The issue of EWSR1 gene rearrangement occurring in different benign and malignant 
tumors was further explored in chapter three and four. 
 In chapter five, we examined the diagnostic significance of genetic changes of 
INI1 and the loss of the corresponding protein and its usefulness in the differential 
diagnosis between epithelioid sarcoma with prominent myxoid changes and myoepithelial 
tumors. 
 Chapter six pays attention to C11orf95-MKL2 as a consistent fusion gene in chondroid 
lipomas and its role in diagnosis. This is an important issue as this rare and morpho-
logically peculiar lipomatous lesion can be easily confused with malignant tumors 
such as extraskeletal myxoid chondrosarcoma and myxoid liposarcoma. 
 In chapter seven, we examined RB1 in cellular angiofibromas. The morphologically 
suggested link with spindle cell lipomas and mammary-type myofibroblastomas as 
documented in the current WHO classification was also further analysed.
 In chapter eight, desmoid fibromatosis of the head and neck in the children 
population is reported. These lesions are clinicopathologically not well-defined against 
other spindle cell lesions in the head and neck region and its molecular analysis was 
expected to be helpful. 
types as mentioned above. The preprogrammed nature of tumor stem cells explains 
why some sarcomas resemble their mature counterpart (eg. low grade leiomyo-
sarcoma, well differentiated liposarcoma).1 On the other hand, some sarcomas show 
a more primitive phenotype (e.g. Ewing sarcomas and alveolar rhabdomyosarcomas) 
closely resembling precursor cells and not always show a specific line of differentiation. 
The histogenesis of these and other sarcomas with no known normal cell counterparts 
could reflect a unique genetic makeup that has created peculiar tumor phenotypes.1
 The origin of the stem cells or precursor cells is not clear, but it seems likely that 
many of them arise from the local, organ-specific pool of stem cells. In addition, data 
indicate that some soft tissue components are replenished from stem cells of bone 
marrow origin.1,6,8 
Genetics 
Tumors are genetic diseases with clonal expansion of neoplastic cells based on 
cancer-gene mutations playing a role in signal transduction pathways. The process of 
tumorigenesis is initiated when a replication-component (cell stem cell or partially 
differentiated descendent of a stem cell) acquires a mutation in a ‘gatekeeping’ pathway 
that endows it with a selective growth advantage.9,10
 Increasing recognition of specific and/or recurrent genetic abnormalities in 
mesenchymal tumors and the growing use of genetic tests have aided in the definition 
of tumor types and the resolution of cellular origin.1 
 In cancer, alterations of oncogenes and tumor suppressor genes are quite common. 
Oncogenes achieve their effects through increased or deregulated activity of one of 
the two copies. This activation can be due to a mutation that alters the sequence 
of the protein with gain of function, increased copy number changes (amplification), 
or a translocation that brings its expression under the control of the regulatory 
sequences (promoter) of another gene, or to a combination of the above. In addition, 
translocations that fuse the coding sequences of two genes to generate chimeric 
proteins are generally considered a special variety of oncogenes, known as fusion 
oncogenes. There are numerous examples of these in soft tissue tumors, especially 
sarcomas.3,11
 Tumor suppressor genes, in contrast, typically exert their oncogenic effects 
through a loss of both functional gene copies. This can be caused by one or more of 
the following mechanisms: a mutation that result in a truncated or inactive protein, 
mutations that result in a dominant negative protein that interferes with the function 
of the normal protein produced by the remaining unmutated gene copy, large 
deletions affecting the gene, replacement of the remaining unmutated copy (loss of 
heterozygosity by mitotic recombination), reduced expression due to hypermethylation 
of the gene’s regulatory sequences, or interruption of the gene by a non-recurrent 
translocation.3 
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CHAPTER 2 EWSR1 IN CUTANEOUS MYOEPITHELIAL TUMORS
Introduction
Cutaneous myoepithelial tumors form a continuous clinicopathologic spectrum 
ranging from benign mixed tumor to myoepithelioma and myoepithelial carcinoma. 
Although mixed tumors are not uncommon, purely myoepithelial tumors are very 
rare and only few and small series have been reported.1-4
 The presence of preexisting myoepithelial cells in the skin and viscera (e.g. 
salivary glands, breast and lung) renders probably a pathogenetic difference with 
myoepithelial tumors of the soft tissue in which a normal counterpart does not exist.
 As a consequence of the variability of myoepithelial cells, different morphologic 
patterns and a heterogeneous immunophenotype with alternating positivity for 
epithelial (keratins, EMA), myogenic (ASMA and calponin) and neurogenic markers 
(S100 and GFAP) occur.1-6 Although criteria for malignancy in myoepithelial tumors 
of soft tissue have been established by moderate to severe nuclear atypia, the 
minimal criteria for malignancy among myoepithelial neoplasms of the skin remain 
uncertain.4,6,7 
 Hornick and Fletcher (2004) reported that increased mitotic activity (up to 6 
mitoses/10 HPF) among cytologically benign cutaneous myoepitheliomas might 
predict recurrence and metastases.4 Furthermore, it has been suggested that in the 
absence of malignant cytomorphology and confirmed metastatic disease, infiltrative 
margins, satellite tumor nodules, tumor necrosis and involvement of deep structures 
are ominous signs.8 Fully malignant myoepitheliomas with malignant cytomorphology are 
known for their potential of aggressive behavior like their soft tissue counterparts.6,9 
 A recently published study showed that a subset of myoepithelial tumors especially 
in the soft tissues harbor EWSR1 rearrangement with different fusion partners, and 
these genetic changes were reported in only two of six of cutaneous myoepithelial 
neoplasms.10 Therefore it seemed appropriate to look for genetic similarities in a 
larger cohort of cutaneous myoepithelial tumors.
Material and Methods 
The cases were retrieved from the (referral) files of 2 of the authors (TM, HK), and 
clinical details and follow-up were obtained from the referring physicians. In all cases, 
the tissue was fixed in 4% buffered formalin, routinely processed and embedded in 
paraffin; 2-4 µm thick sections were stained with hematoxylin and eosin and immuno-
histochemically by the labelled streptavidin biotin technique using commercially 
available antibodies listed in Table 1. Appropriate positive and negative controls were 
used throughout.
Abstract
Cutaneous myoepithelial tumors form a clinicopathologic spectrum ranging from 
mixed tumor to myoepithelioma and myoepithelial carcinoma. 
 Recently, EWSR1 rearrangement has been described in a subset of soft tissue 
myoepithelial tumors, whereas the cutaneous counterparts showed this aberration 
in a minority of cases. This raises the question whether cutaneous myoepithelial 
tumors have comparable genetic alterations.
 We examined 18 cases of cutaneous myoepithelial tumors arising in seven female 
and eleven male patients (age range, 34-86 years; mean, 58 years). Eight mixed 
tumors occurred at the head, and one at the scrotum. Six myoepitheliomas arose at 
the extremities, and one case each at the back and head. One myoepithelial carcinoma 
occurred at the cheek. The tumor size ranged from 0.3 – 1.7 cm (mean, 1.0 cm). All mixed 
tumors and three myoepitheliomas were limited to the dermis. Four myoepitheliomas 
and the myoepithelial carcinoma involved the subcutis. Mixed tumors and myoe-
pitheliomas were composed of myoepithelial cells with a variable cytomorphology, 
architecture and stromal background. Ductal structures were seen by definition in 
mixed tumors. The myoepithelial carcinoma represented an infiltrative dermal 
neoplasm consisting of atypical spindle cells.
 Immunohistochemically, all cases tested were positive for EMA and calponin 
whereas S100, CK, ASMA and GFAP were expressed in 90%, 80%, 78% and 50% of the 
cases tested respectively.
 By fluorescent in situ hybridization analysis, 7 out of 16 cases (44%) exhibited 
EWSR1 rearrangement. Four of them were mixed tumors, two were myoepitheliomas 
and one was a myoepithelial carcinoma confirming that these lesions represent a 
spectrum of dermal myoepithelial tumors. 
 Follow-up information, available for five patients (including the patient with a 
myoepithelial carcinoma), revealed no evidence of disease in all cases (range, 6 – 72 
month).
 Our study provides a genetic relationship of myoepithelial tumors of the skin 
with their counterparts in soft tissue, bone and visceral localization by sharing EWSR1 
rearrangement.
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Mixed tumors were smaller than myoepitheliomas (0.9 cm vs. 1.2 cm). All mixed 
tumors and three myoepitheliomas were limited to the dermis; four myoepitheliomas 
showed involvement of the subcutis. In one myoepithelioma, the depth was not 
known. The myoepithelial carcinoma infiltrated the subcutis (Table 2). 
 Histologically, all mixed tumors were well circumscribed; seven had a nodular 
and two a nodular cystic architecture (Figure 1). Ductal structures were present by 
definition in all cases (Figure 2), sometimes cystic dilated and sometimes with apocrine 
features (n=3). Cribriform structures were present in one case. The myoepithelial 
component was arranged around ducts and also in nests, cords and strands, solid and 
reticular. Although epithelioid myoepithelial cells occurred in all cases, spindle cells 
were present in three cases and plasmocytoid cells in five cases. One case showed 
Fluorescent in situ hybridization analysis
For the detection of a translocation involving the EWSR1 gene on 22q12 and the FUS 
gene on 16p11 a directly FITC/Rhodamine-labeled break apart probe (Abbott, Bergisch 
Gladbach, Germany) was used.
 Fluorescent in situ hybridization analysis (FISH) was performed on 3 µM sections 
of formalin-fixed, paraffin-embedded tissue after baking at 65°C for 16 h, deparaffini-
zation with xylene and rehydration with ethanol. All tissue sections were pretreated 
with a 30% solution of Oncor pretreatment powder in 2xSSC and digested for 10 
minutes with Proteinase K following the instructions of the suppliers (Q-Biogene, 
Heidelberg, Germany). After a second rehydration step, the probes were applied to 
the sections and the covered slides were sealed with rubber cement, heat-denatured 
and hybridized at 37°C for 16 h. All sections were counterstained with DAPI II in 
mounting medium (125 ng/ml, Abbott, Bergisch Gladbach, Germany) and visualized 
under a Zeiss Axioplan microscope using a HBO100 lamp and the appropriate filters 
for the three fluorescent dyes. A negative control has been used in each case. A case 
was considered having a break in case 10 of 50 counted tumor cells showed separation 
of a red and green signal.
Results
Eighteen cases were studied. Clinical data are shown in Table 2. Briefly, there were 
7 females and 11 males with an age range of 34-86 years (mean, 58 years; median, 
56 years). 
 Mixed tumors (n=9) occurred mostly on the head (n=8), whereas one was 
localized at the scrotum. Most of the myoepitheliomas (n=6) occurred at the 
extremities, one case each arose on the back and head. There was one myoepithelial 
carcinoma occurring at the cheek. The tumor size ranged from 0.3 – 1.7 cm (mean 1.0 cm). 
Table 1  Details of used immunohistochemical antibodies
Antibody Clone Dilution Source
ASMA 1A4 1:500 DAKO
EMA Mc5 1:400 BioGenex, San Ramon, USA
Pancytokeratin MNF116 1:500 DAKO
S-100 protein polyclonal 1:2000 DAKO
GFAP GA-5 1:200 DCS, Hamburg
Calponin CALP 1:400 DAKO, Glostrup, Denmark
Table 2  Clinical data and histological diagnosis 
Case Sex/ Age Location SC size  
(cm)
diagnosis RS follow-up
 1 m/34 y occipital - 1.0 mixed tumor RM NA
 2 m/86 y scrotum - 1.2 mixed tumor RM NA
 3 m/48 y face - 0.5 mixed tumor R0 NA
 4 m/55 y nose - 0.3 mixed tumor RM NA
 5 m/72 y frontoparietal -   1.2 mixed tumor RM NED, 51
 6 m/57 y temple - 0.5 mixed tumor R0 NED, 12
 7 f/61 y parietal - 1.7 mixed tumor R1 NA
 8 f/54y face - 0.4 mixed tumor R0 NA
 9 m/68 y face - 0.8 mixed tumor R0 NA
 10 f/51 y back + 1.5 myoepithelioma, rec RM NA
 11 m/55 y distal lower leg + 1.2 myoepithelioma R0 NED, 6
 12 m/50 y ear - 1.5 myoepithelioma R1 NA
 13 f/65 y arm - 1.5 myoepithelioma R0 NED, 17
 14 m/66 y thumb + 1.5 myoepithelioma RM NA
 15 f/49 y finger - 0.5 myoepithelioma R0 NA
 16 f/45 y thigh + 0.7 myoepithelioma R0 NA
 17 m/57 y plantar NA NA myoepithelioma R1 NA
 18 f/70 y cheek + 0.8 myoepithelial ca R0 NED, 72
SC, subcutaneous; RS, resection status; NA, not available
R0, complete resection; RM, marginal resection; R1, microscopically positive resection margins; NED, 
no evidence of disease; rec, recurrence; ca, carcinoma
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focally clear cells. Metaplastic fat cells were a feature in Cases 1, 2, and 7 and squamous 
metaplasia in Cases 1 and 6. Ischemic central necrosis was seen in Case 5. No case 
showed mitotic figures and in Case 3 focal moderate atypia was noted. The stroma 
was myxoid at least focally in all cases, chondroid in four cases, hyaline and/or 
collagenous in five and three cases, respectively.
 Three of the myoepitheliomas displayed a multinodular and three a nodular pattern, 
one of them with an epidermal collarette (Figure 3). A nodular-cystic appearance was 
noted in one case. One neoplasm was not sharply demarcated. 
 In each myepithelioma, different cell types were present. Two tumors contained 
mainly spindle cells and some epithelioid cells mostly arranged in bundles (Figure 4). 
Two tumors with a nested pattern had a predominantly plasmocytoid/epithelioid 
composition. In one of them double nuclei were present as seen in plasma cells. 
Epithelioid and spindle cells were observed in four cases accompanied by clear cells 
in Case 10 and plasmocytoid cells in Case 12. Strands, cords and nests were found in 
the latter cases (Figure 5). The matrix was at least focally myxoid in five cases, 
collagenous/hyaline in five cases, and focally chondroid in one case. Adipocytic differ-
entiation occurred in one case. Little atypia was present in Case 11 and moderate 
atypia in Case 13 (Figure 6). The last one and Case 14 had 1 mitotic figure per 10 HPF, 
whereas in all other cases mitoses were absent.Figure 1  All mixed tumors had a nodular architecture (Case 2)
Figure 2   Glandular structures and a varying number of myoepithelial cells were 
present in all mixed tumors (Case 2)
Figure 3   Case 13 was an exophytic lesion with an epidermal collarette
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 The myoepithelial carcinoma (Case 18) was described earlier by the authors 
(Mentzel et al. 2003) and represented an infiltrating neoplasm composed of atypical 
spindle cells with enlarged and pleomorphic nuclei containing prominent nucleoli. 
There were 5 mitoses per 10 HPF. Focal tumor necrosis was present (Figure 7). 
 Immunohistochemical results are shown in Table 3. All cases tested were positive 
for EMA and calponin whereas S100, CK, ASMA and GFAP were expressed in 90%, 
80%, 78% and 50% of the cases tested, respectively (Figure 8 and 9). 
 By FISH analysis, 7 out of 16 cases (44%) exhibited EWSR1 rearrangement. Four of 
them were mixed tumors, two were myoepitheliomas and one was a myoepithelial 
carcinoma (Figure 10). Separation of the signal was generally seen in at least 20% of the 
nuclei. There were no morphological differences between positive and negative cases.
 FUS gene rearrangement examined in the EWSR1 negative instances was not 
detected in any of them (n=9) (Table 4).
 In nine cases, the tumors were excised with wide tumor-free margins, and in six 
cases, the tumor were marginally excised. Microscopically tumor positive margins 
were observed in three cases (Table 2). 
 Follow-up data were available in five patients (two with myoepitheliomas, two 
with mixed tumors, one with a myoepithelial carcinoma) without evidence of disease 
during a follow-up time with a range of 6 – 72 month (mean, 32 month) (Table 2).
Figure 4   Case 11 showed predominantly spindle-shaped myoepithelial cells and also 
metaplastic adipocytes
Figure 5   Case 10 was mainly composed of epithelioid cells with a predominantly 
nested growth pattern. Note the chondromyxoid stroma
Figure 6   Moderate atypia was seen in Case 13. Note the reticular architecture and 
the myxoid matrix
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Figure 7   The myoepithelial carcinoma consisted of atypical spindle-shaped cells with 
infiltrative growth (Case 18)
Table 3  Immunohistochemical Results
Case CK EMA    ASMA Calponin S100 GFAP
3 + nd nd nd + nd
9 nd nd f+ nd + nd
10 + nd f+ f+ + +
11 f+ + + + f+ nd
12 + nd + nd nd -
13 - + - nd + nd
14 + f + nd f+  + nd
15 + nd f+ nd f+ nd
16  - + + nd f+ nd
17 + nd - nd + nd
18 + + + nd - nd
Total +
8/10 5/5 7/9 3/3 9/10 1/2
80% 100% 78% 100% 100% 50%
nd, not done; f, focally
Figure 8   The atypical spindle cells expressed EMA in Case 18
Figure 9   Expression of ASMA in the myoepithelial carcinoma
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Discussion
Cutaneous myoepithelial tumors are divided into mixed tumors and myoepithelio-
mas depending on the occurrence of ductal structures defining the former.2,3 They 
also include myoepithelial carcinomas which are defined by atypical cytological 
features.3,4 In the absence of atypia, high mitotic index, local invasion and tumor 
necrosis should raise concern.4,8 
 Earlier studies suggested that cutaneous myoepitheliomas and their soft tissue 
counterparts represent points along a clinicopathologic spectrum that was apparently 
extended to include myoepithelial tumors of the bone and of some visceral sites 
(lung). 1,2,5,10 Although this entity, in the above described localizations, is well-estab-
lished by now, the protean morphological and immunohistochemical range is still 
hampering the histopathological diagnosis, and the true frequency of these neoplasms 
is unclear until today. 
 This study also mirrors the morphological and immunohistochemical heterogeneity 
by the presence of a variable (immuno)phenotype in all cases. A (chondro)myxoid/
hyaline matrix was almost always existent and adipocytes as a heterologous element 
were seen in four of our cases. All these observations are well-reported earlier.1-4,6 
Table 4  FISH results for EWSR1 and FUS rearrangement
Case EWSR1 FUS
1 + (17/50) nd
2 + (19/50) nd
3 + (11/50) nd






10 + (14/50) nd




15 + (12/38) nd
16 x x
17 - -
18 + (10/50) nd
+, break apart signal/rearrangement (in out of nuclei counted); -, no break apart signal/rearrangement; 
nd, not done; x, analysis failed
Figure 10   FISH of a myoepithelioma (Case 15) with a break apart signal for EWSR1
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 The occurrence of EWSR1 rearrangement in mixed tumors, myoepitheliomas and 
rare  myoepithelial carcinomas emphasizes that these lesions belong to a spectrum of 
cutaneous myoepithelial neoplasms. 
 Furthermore, EWSR1 rearrangement found in 44% of cutaneous myoepithelial 
tumors in our series, provide a genetic link with their counterparts in soft tissue, bone 
and the lung. Most of the reported EWSR1 rearrangements occur in soft tissue 
myoepithelial tumors which means that 45% of them show this abnormality.10 This is 
in concert with our results in cutaneous tumors. POUF5F1 is one of the described 
fusion genes in the soft tissue tumors and is associated with clear cell morphology 
and younger age.10 Other known fusion partners are PBX1 and ZNF444.10-12 In 42% of 
the described EWSR1 rearranged cases these fusion partners have been identified so 
far. For PBX1 and POU5F1 the same frequency was detected and a EWS1-ZNF444 
fusion was seen in only one case of the lung.10
 When we consider the low incidence of FUS rearrangement in the series by 
Antonescu et al.10 with one positive pulmonal myoepithelial tumor of total 66 cases, 
it is not surprising that we did not find a FUS gene rearrangement in our cases.10
 Hidradenoma, a biphasic epithelial skin appendage tumor with occurrence of 
ductal/ glandular and cystic structures, earlier thought to be a clear cell myoepithelioma,13,14 
possess in a subset of cases the specific translocation CRTC1-MAML2,  which has been 
also described in mucoepidermoid carcinomas and Warthin’s tumors of salivary 
glands.15,16 One study demonstrated the occurrence of EWSR1- POUF5F1 fusion in 
hidradenomas,17 whereas Antonescu et al10 did not find an EWSR1 rearrangement in 
five eccrine hidradenomas.10 Therefore, one could speculate whether these described 
lesions by Möller et al are more related to myoepithelial tumors.17
 The much more common occurring and investigated myoepithelial tumors of the 
salivary glands are known for a different genetic background, which contains 
rearrangements of PLAG1 and HMGA2.18
 A differential diagnosis of cutaneous myoepithelial tumors in our opinion 
represents epithelioid sarcoma, especially the very rarely occurring myxoid variant. 
Their occurrence is mostly as in myoepitheliomas at the distal extremities. This 
myxoid variant always shows at least focally classical features of epithelioid sarcoma.19 
Although there is an immunohistochemical overlap with positivity for keratin and 
EMA, INI1 protein, absent in the majority of cases of epithelioid sarcoma, is a reliable 
marker for supporting the diagnosis.20-22 In contrast, cutaneous myoepithelial tumors 
have a retained INI1 protein in all of our cases (data not shown). In this context, it 
should be noted that in a subset of myoepithelial carcinomas of soft tissue the INI1 
protein is absent.9 Another helpful discriminating marker is CD34 which is at least in 
50% of epithelioid sarcomas positive.20,23,24 Although genetic aberrations in INI1, 
located on 22q11, are reported in epithelioid sarcoma, EWSR1 rearrangements are 
never described.19,22,25,26 
 On histomorphological grounds, extraskeletal myxoid chondrosarcomas and 
ossifying fibromyxoid tumors may also enter the differential diagnosis. Although 
extraskeletal myxoid chondrosarcomas are classically located in the deep soft tissues, 
ossifying fibromyxoid tumors are commonest located in the subcutis and involvement 
of the skin has rarely been reported. These tumors show a distinctive lobulation and 
in most cases a bone shell is evident.27,28,29 Metaplastic bone formation known in 
soft tissue myoepithelial tumors is not described in skin lesions.1-8 Moreover, the 
intratumoral cytological and architectural heterogeneity of myoepithelial tumors is 
not a feature of ossifying fibromyxoid tumors in which uniform round to oval cells in 
cords and nests set in a myxohyaline stroma.4,6,7 Immunohistochemical stains in this 
setting are of limited value because of the overlap with positivity for S100, GFAP, 
myogenic markers and rarely also keratins.4,6,7,27-29 Even though in a small number of 
cases investigated, ossifying fibromyxoid tumors show no abnormality in EWSR1.10 
In summary, our study demonstrated that cutaneous myoepithelial tumors harbor 
EWSR1 rearrangement in a subset of cases and therefore are genetically related to 
soft tissue and bone myoepithelial tumors and the visceral counterpart in the lung. 
Regarding the fusion genes of EWSR1 in cutaneous tumors, further investigations are 
mandatory. 
 In addition, the relative low incidence of EWSR1 rearrangement in myoepithelial 
tumors comparing with other tumors harboring translocations, alternative genetic 
mechanisms, more specifically, rearrangements of other genes have yet to be discovered. 
Apparently plays FUS here a tangential role.10 
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Introduction
Soft tissue myoepithelial tumors, a recently defined entity, include benign and 
malignant lesions characterized by a broad morphological and immunohistochemical 
spectrum [1]. 
 The first large molecular study demonstrated EWSR1 rearrangements in 
approximately 45% of soft tissue myoepithelial tumors with identified fusion genes 
such as POU5F1, PBX1 and ZNF444 in 42% of them.2 
We describe herein a soft tissue myoepithelioma arising in the pelvis with an 
EWSR1-ATF1 fusion, therefore extending the spectrum of partner genes of EWSR1 in 
this tumor type.
Clinical History
A 57-year-old male patient had a 14 cm large tumor in his pelvis with erosion of the 
sacrum and displacement of urinary bladder and rectum.
 A transabdominal biopsy was taken. The tumor was considered as irresectable, 
and the patient received radiotherapy without obvious signs of regression. Three 
years later, he experienced local tumor progression with sacral nerve root compression 
and renal insufficiency due to hydronephrosis. Death from these local problems 
ensued 43 months after the initial diagnosis. Metastases were not detected.
Material and methods
The tumor tissue from the biopsy was partly snap frozen and fixed in 4% buffered 
formalin, routinely processed, and embedded in paraffin; 2-to 4-µm thick sections 
were stained with hematoxylin and eosin and immunohistochemically by the labelled 
Streptavidin Biotin technique using commercially available antibodies listed in Table 1. 
Appropriate positive and negative controls were used throughout.
 RNA extracts from fresh frozen tissue were subjected to reverse transcription- 
polymerase chain reaction (RT-PCR) and assessed for different gene fusions that were 
established in 2001 for sarcomas, as Ewing sarcoma (EWSR1-FLI1/ERG), synovial 
sarcoma (SS18-SSX1/2), extraskeletal myxoid chondrosarcoma (EWSR1-NR4A3), 
myxoid liposarcoma (FUS-DDIT3) and clear cell sarcoma (EWSR1-ATF1) because the 
histological and immunohistochemical features did not fit with any of the widely 
accepted entities at that time. The diagnosis of a clear cell sarcoma was made owing 
to the fusion product of EWSR1-ATF1. When we reevaluated this case recently, the 
diagnosis was changed into myoepithelioma owing to morphology and immunohisto-
Abstract
Soft tissue myoepithelial tumors, a recently defined entity, include benign and 
malignant lesions showing a considerable morphological and immunohistochemical 
heterogeneity. 
 EWSR1 rearrangements are well recognized in this tumor type, and some of the 
partner genes have been identified. Herein we describe a soft tissue myoepithelioma 
arising in the pelvis with an EWSR1-ATF1 fusion, therefore extending the spectrum of 
partner genes of EWSR1.
 In addition, this case indicates that there are overlapping genetic features of 
myoepithelial tumors, clear cell sarcoma, angiomatoid fibrous histiocytoma, and 
hyalinising clear-cell carcinoma of salivary gland.
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Results
Histologically, the tumor showed a trabecular pattern of uniform-appearing epithelioid, 
ovoid or focally somewhat more spindled cells with mainly round nuclei without 
prominent nucleoli. The limited amount of cytoplasm was clear to eosinophilic. Cytological 
atypia was absent and mitotic figures were scarce. There was an obvious chondro- 
myxoid background (Figure 1). 
 The immunhistochemical features consisted of positivity for S-100 (Figure 2) and 
focally for EMA (Figure 3), whereas Pan-CK (MNF116, AE1/3), CAM5.2, α-smooth 
muscle actin, p63, glial fibrillary acidic protein, HMB-45, Melan-A, and calponin were 
negative.
 The EWSR1-ATF1 fusion detected by using RT-PCR was due to an in-frame fusion 
of exon 8 of EWS with exon 4 of the ATF1 gene (Figure 4).
 In 2 other soft tissue myoepithelial tumors tested, we did not find an EWSR1/ATF1 
chimeric transcript (data not shown).
 By FISH analysis, the tumor exhibited an EWSR1 rearrangement. A break-apart 
signal was seen in 23 out of 50 counted nuclei (Figure 5). 
chemisty. Moreover, we repeated RT-PCR for EWSR1-ATF1 and additionally applied 
EWSR1-fluorescence in situ hybridization (FISH) analysis as described below:
Translocation-specific PCR
cDNA synthesis was performed in a 24-ul reaction containing 1 ug of RNA, 1 ug of 
random hexamers (Promega, Madison, WI, USA) and 20 nmol dNTPs (Invitrogen, 
Carlsbad, CA, USA) and heated at 65 °C for 5 min. Next 2 ul of RNasin (Promega), 8 ul 
of 5x first strand buffer (Invitrogen), 4 ul of 0.1 M DTT (Invitrogen) and 2 ul of 
Superscript II (Invitrogen) were added and the sample was heated accordingly: 10 
minutes at 20 °C, 60 minutes at 42 °C and 3 minutes at 95 °C. cDNA was stored at -20 °C.
 Potential translocation-specific EWSR1-ATF1 fusion products were detected using 
primers targeting EWSR1 (exon 7: TCCTACAGCCAAGCTCCAAGTC and exon 8: GATTT-
GATCGTGGAGGCATGAG, RefSeq: NM_005243.1) and ATF1 (exon 5: GTACTCCATCTGT-
GCCTGG, RefSeq: NM_005171.2). 
 DNA amplification was performed in duplicate in a PTC 200 Thermal Cycler (MJ 
Research, Waltham, MA, USA). The PCR was started with 10 minutes at 95 °C and 
followed with 38 cycles of denaturation at 95 °C for 30 seconds, annealing at 58 °C for 
30 seconds and extension at 72°C for 60 seconds, followed by a final extension at 
72°C for 7 minutes and cooling down for 5 minutes at 20°C. PCR products were 
analyzed by 2% agarose gel electrophoresis.
Fluorescent in situ hybridization (FISH) analysis
For the detection of an EWSR1 gene rearrangement (22q12) a direct fluorescein 
isothiocyanate/rhodamine-labeled break apart probe (Abbott, Bergisch Gladbach, 
Germany) was used.
 FISH was performed on 3 µM sections of formalin-fixed, paraffin-embedded 
tissue after baking at 65°C for 16 hours, deparaffinization with xylene and rehydration 
with ethanol. All tissue sections were pretreated with a 30% solution of Oncor 
pretreatment powder in 2xSSC and digested for 10 minutes with proteinase K 
following the instructions of the suppliers (Q-Biogene, Heidelberg, Germany).  After a 
second rehydration step, the probes were applied to the sections and the covered 
slides were sealed with rubber cement, heat-denatured, and hybridised at 37°C for 16 
hours. All sections were counterstained with DAPI II in mounting medium (125 ng/ml, 
Abbott, Bergisch Gladbach, Germany) and visualized under a Zeiss Axioplan 
microscope using a HBO100 lamp and the appropriate filters for the 3 fluorescent 
dyes. A negative control was used.
Table 1  Details of used immunohistochemical antibodies
Antibody Clone Dilution Source
ASMA 1A4 1:500 DAKO, Glostrup, Denmark
EMA Mc5 1:400 BioGenex, San Ramon, USA
Pan-cytokeratin MNF116 1:500 DAKO, Glostrup, Denmark
Pan-cytokeratin AE1/3 1:50 DAKO, Glostrup, Denmark
CK8/18 CAM 5.2 1:50 Becton Dickinson, San Jose, USA
S-100 polyclonal 1:2000 DAKO, Glostrup, Denmark
Calponin CALP 1:400 DAKO, Glostrup, Denmark
HMB-45 HMB-45 1:300 DAKO, Glostrup, Denmark
Melan A Clone A103 1:50 DAKO, Glostrup, Denmark
GFAP GA-5 1:200 BioGenex, San Ramon, USA
p 63 4A4 1:400 DAKO, Glostrup, Denmark
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Figure 1   Trabecular and reticular arrangement of epithelioid cells set in a chondro- 
myxoid stroma
Figure 2   The tumor showed expression of S-100 Figure 4   Sequence of RT-PCR product showing a fusion of EWSR1 exon 8 to ATF1 
exon 4 in the chimeric transcript
Figure 3   Immunostaining for EMA was focal
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 Recently, EWSR1 gene rearrangements were detected in both benign and malignant 
myoepithelial tumors of soft tissue, bone, skin, and the lung. The identified partner genes, 
found in approximately 20% of all cases, are POU5F1, PBX1 and ZNF444. Most of these 
fusions correlated with deep soft tissue localization. Furthermore, distinctive clear 
cell morphology and young patient age were strongly associated with EWSR1-POU5F1.2
 Until now, EWSR1-ATF1 has never been described in myoepithelial tumors, but it is 
well known in clear cell sarcoma and angiomatoid fibrous histiocytoma.6 In a recently 
published study, Antonescu et al.7 demonstrated the occurrence of this gene fusion 
also in hyalinising clear-cell carcinoma of salivary gland and reported novel break 
points (EWSR1 exon 11; ATF1 exon 3). Interestingly, these tumors show superficially 
resemblance with some of the myoepithelial soft tissue tumors, but lack true 
myoepithelial features by immunohistochemistry.7 On the contrary, myoepithelial 
differentiation was supposed by others based also on immunohistochemical data.8
 Clear cell sarcomas, mostly present on the distal extremities in young adults, 
have also been reported at unusual sites, such as pelvis, kidney, gastrointestinal 
tract, skin, breast and mediastinum.6,9-16 Although, classical histological features as 
first described by Enzinger9 are present in the majority of cases, morphological 
variations are also recorded. The latter include an alveolar and seminomalike pattern, 
rhabdoid cellular features, polymorphic cells and small intercellular pools of mucoid 
material.9,12,13,17  
 In contrast, our case consisted of uniform-appearing epithelioid cells arranged in 
a trabecular pattern. Prominent nucleoli, a cytological hallmark of clear cell sarcoma, 
were not discernible. As is typical for myoepithelial tumors, a prominent chondromyxoid 
matrix was present. On the other hand, a nested and short fascicular growth pattern 
accompanied by a delicate fibrous network in clear cell sarcoma and wreath-like 
multinucleated giant cells were absent.6
 EMA and S100, positive in the here described case, show variable coexpression 
with myogenic markers (calponin, α-smooth muscle actin, desmin), glial fibrillary acidic 
protein, and keratins in myoepithelial tumors.1,4-6
 However, a recent study described EMA positivity in one third of the cases of 
clear cell sarcoma but the overwhelming majority of cases expressed S100 in 
combination with HMB45 and/or Melan A and/or MITF.13 Traces of keratin expression 
in clear cell sarcomas were rarely described.14 
 Angiomatoid fibrous histiocytoma, with its distinct morphology, is easily distin-
guishable from myoepithelial tumors. This mostly superficially localized circumscribed 
lesion is defined by sheets of bland spindle to ovoid cells, peripheral lymphocytic 
infiltrate and blood-filled cystic cavities and behaves mainly in a benign fashion. 
Expression of desmin and muscle actin in a subset of cases led to the hypothesis of a 
myoid nature. EMA can also be positive and is therefore not discriminating in this 
setting.6
Discussion
Stout and Gorman described the first case of a soft tissue myoepithelial tumor in 
1959, and Kilpatrick et al.4 extended the concept of this tumor type by including 
metastatic cases. When Hornick and Fletcher5 reported on the largest series to date, 
they proposed moderate to severe atypia as criterion for malignancy. A considerable 
heterogeneity in architecture, cytology, stroma reaction and immunohistochemistry 
owing to the flexibility of myoepithelial cells is a hallmark of this entity.1,5,6 
Figure 5   EWSR1 gene rearrangement by FISH (break-apart signal)
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 In summary, our case represented a myoepithelial neoplasm of soft tissue with 
an EWSR1-ATF1 chimeric transcript. A malignant nature of this tumor was not obvious, 
because of its bland cytomorphology. However, the unfavourable localization of a 
large tumor within the pelvis made surgery impossible and a locally aggressive 
behaviour despite radiotherapy resulted in death of the patient 3.5 years after the 
initial diagnosis.
 Additionally, this case indicates that there are overlapping genetic features of 
myoepithelial tumors, clear cell sarcoma, angiomatoid fibrous histiocytoma and 
hyalinising clear-cell carcinoma of salivary gland. The differences in morphology and 
immunohistochemistry between the mentioned soft tissue lesions allow their 
distinction, which, naturally, is mandatory for patient management. 
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Introduction
Myoepithelial tumors of the soft tissue were initially characterized in a series by 
Kilpatrick et al.1 Later on, criteria for malignancy were established and the clinico-
pathological features were expanded.2,3 Histologically, these tumors show the same 
broad variation in morphology as seen in their salivary gland counterparts.1-4 
 Extraskeletal myxoid chondrosarcomas (EMCs) reveal a cord- or lace-like arrangement 
of small round to spindle-shaped cells with distinct eosinophilic cytoplasm distributed 
in a prominent myxoid stroma. In cellular lesions (cEMCs), amounting to one third of 
the cases, there is a greater morphological diversity.5-11 
 Although the age range is broad for both entities, the peak incidence for EMC is the 
sixth and for myoepithelial tumors the fourth decade.2,4,12 Furthermore, a significant 
subset of malignant myoepithelial tumors or myoepithelial carcinomas (MECs) occurs 
in children in contrast to EMCs, which show a very low incidence in this cohort.3,5,8,12,13 
Both, myoepithelial tumors and EMCs arise predominantly in the proximal lower 
extremity but EMCs are more often located in the deep soft tissue.2,4,12 
 Whereas EMCs have a protracted clinical course with a 10-year survival rate up 
to 88%, 5,8,14-16 MECs typically demonstrate aggressive behavior, particularly in the 
pediatric population.2,3 Whether or not also cEMCs have a worse prognosis remains 
controversial.5-10
 Histologically, cEMC can be morphologically similar to myoepithelial tumors but 
the latter have, in most of the cases, a broader immunohistochemical profile.2-4,12 
Gene fusions involving NR4A3 (nuclear receptor subfamily 4, group A ,member 3) located 
at 9q22 are characteristic for EMC and have never been described in myoepithelial 
tumors. In contrast, both tumor types harbor EWSR1 (Ewing sarcoma breakpoint 
region 1; 22q12.2) rearrangement.3,12,17-25 
 In this paper, we report herein on the morphological, immunohistochemical and 
molecular overlap of MEC and cEMC. 
Material and Methods
We searched the surgical pathology and referral files of the authors for the diagnoses 
myoepithelial tumors of soft tissue and EMC. Slides were reviewed and the diagnoses 
were based on criteria according to the recent WHO classification.26 Myoepithelial 
tumors with moderate to severe nuclear atypia (vesicular or coarse chromatin, 
prominent, often large nucleoli, or nuclear pleomorphism) and EMCs with cellular 
features were included in our study. Clinical details and follow-up were obtained 
from the referring pathologists (see acknowledgement). Cases 8 and 10 were 
published earlier.3,27,28
Abstract
Myoepithelial carcinoma of soft tissue (MEC) and cellular extraskeletal myxoid 
chondrosarcoma (cEMC) share striking similarities. In this paper, we compare ten MECs 
with 5 cEMCs.
 MEC patients had an equal gender distribution. The age range was 15-76 years 
(mean, 42 years). Tumors were located on extremities, pelvic girdle, vulva, and neck. 
Follow-up, available for 9 patients, ranged from 4 to 85 months (mean, 35 months). 
Five patients were alive without evidence of disease, two were alive with disease and 
two died 8 months after the initial diagnosis. cEMCs were from three males and two 
females with an age range of 37-82 years (mean, 57 years); they presented in extremities, 
shoulder and paravertebral/cervical. Follow-up, available for four patients, ranged from 
6 to 220 months (mean, 61 months). All patients were alive, two with recurrences 
and/or metastases and two without evidence of disease. Morphologically, the 
distinction between these two entities was difficult since all cases exhibited features 
typically seen in myoepithelial tumors. Immunohistochemically, MECs expressed 
pan-keratin (80%), epithelial membrane antigen (57%), S100 (50%), alpha-smooth 
muscle actin (ASMA; 75%), calponin (67%) and p63 (25%). S100 and EMA were 
expressed in 40% of cEMC cases respectively with additional immunoreactivity for 
p63, ASMA and glial fibrillary acidic protein in one case. Pan-keratin was negative in 
all neoplasms. NR4A3 rearrangement was present in four of four cEMCs and in none 
of the MECs. In contrast, three of nine (33%) MECs and four of five (80%) cEMCs 
showed an EWSR1 rearrangement. In summary, MECs and cEMCs share clinical, 
morphological, immunohistochemical and genetic characteristics. The pathognomic 
rearrangement of NR4A3 is a useful diagnostic feature in identifying cEMCs. 
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of 0.1 M DTT (Invitrogen) and 2 µl of Superscript II (invitrogen) were added and the 
sample was heated accordingly: 20 °C for 10 min, 42 °C for 60 min and 95 °C for 3 min. 
For EMC, most potential translocation-specific EWSR1-NR4A3 and TAF15-NR4A3 
fusion products were detected using primers targeting EWSR1 (exon 7: TCCTACAGC-
CAAGCTCCAAGTC and exon 11: GACTCTAGATGATCTGGCAGAC, RefSeq: NM_005243.3), 
TAF15 (TAF15 RNA polymerase II) (exon 6: AGCAGTCAAATTATGATCAGCAGC, RefSeq: 




Clinical details are summarized in Table 2. The MEC cohort consisted of five males and 
five females with an age range of 15-76 years (mean, 42 years). The tumors were 
located on the extremities (n=4) with one case each on the thigh, calf, forearm and 
hand. Other sites were vulva (n=2), gluteal (n=1), sacral (n=1), and the neck region 
(n=1). In one case, the exact anatomic site was not known. Seven MECs were situated 
in the deep soft tissue and two subcutaneous. One superficially located tumor of the 
vulva showed exophytic growth. All patients underwent surgical treatment. Complete 
resection was reached in seven cases and marginal excision in one case. Tumor-positive 
margins were reported in two cases. Follow-up, available for nine patients, ranged 
from 4 to 85 months (mean, 35 months). Five patients were alive without evidence of 
disease at 12, 34, 39, 60 and 70 months, respectively. Two patients were alive with 
disease 4 and 85 months after the initial diagnosis, the latter with a second local 
recurrence. Two patients died of tumor 8 months after the initial diagnosis. Case 10 
was the first local recurrence on the hand with secondary bone involvement. Three 
patients presented with lung metastases. Involvement of regional lymph nodes was 
additionally observed in two of them, and one patient had bone metastases.
 The five cases of EMC were from three males and two females with an age range 
37-82 years (mean, 57 years). Two lesions were located in the deep soft tissue of the 
thigh and one in the subcutis and soft tissue of the shoulder. One tumor each arose at 
the ankle and paravertebral/cervical region. All patients but one (n=4) underwent 
resection. Tumor free resection margins were reported in three cases (wide margins 
in two cases and marginal resection in one case). In Case 14, the resection status was 
not known. Follow-up, available for four patients, ranged from 6 to 220 months 
(mean, 61 months). No patient died of disease so far. Case 15 was the 4th recurrence 
of a tumor with primarily classical morphological features. This patient had also 
pulmonary spread. Another patient was known with regional lymph node involvement 
(Case 13). 
In all cases the tissue was fixed in 4% buffered formalin, routinely processed and 
embedded in paraffin; 2-4 µm thick sections were stained with hematoxylin and 
eosin. Immunohistochemistry methods consisted of the labelled Streptavidin Biotin 
technique using commercially available antibodies as listed in Table 1. Appropriate 
positive and negative controls were used throughout.
Fluorescence in situ hybridization analysis
Fluorescence in situ hybridization (FISH) was performed as described earlier. For 
EWSR1 a directly FITC/Rhodamine-labeled break apart-probe (Abbott, Bergisch 
Gladbach, Germany) was used.29 FISH probes to detect a NR4A3 rearrangement 
(break apart-probe) were generated in-house. BAC clones RP11-624K13 (centromeric), 
RP11-412F16 (centromeric), RP11-121L12 (telomeric) and RP11-467B11 (telomeric) were 
obtained from the BACPAC Resources Center (Oakland, CA). Clones were either 
labeled with biotin or digoxigenin (DIG) using a nick translation kit, according to 
manufacturer’s instructions (Roche, Basel, Switzerland). Copy numbers of chromosome 9 
were assessed using a centromere probe (CEP9). A negative control has been used for 
each tumor. A case was considered having a break when at least 10 of 50 counted 
tumor cells (20%) showed separation of a red and green signal.
Reverse transcription polymerase chain reaction (RT-PCR)
RNA was isolated from formalin-fixed, paraffin-embedded material by proteinase K 
digestion, followed by phenol/chloroform extraction and n-propanol precipitation. 
cDNA synthesis was performed in a 24-µl reaction containing 1 µg of RNA, 1 µg of 
random hexamers (Promega) and 20 nmol dNTPs (Invitrogen) and heated at 65 °C for 
5 min. Next, 2 µl of RNasin (Promega), 8 µl of x 5 first strand buffer (Invitrogen), 4 µl 
Table 1  Details of used immunohistochemical antibodies
Antibody Clone Dilution Source
ASMA 1A4 1:500 DAKO, Glostrup, Denmark
EMA Mc5 1:400 BioGenex, San Ramon, USA
CD34 HPCA-1 1:100 BD Biosciences, San Jose, USA
Pan-cytokeratin MNF116 1:500 DAKO, Glostrup, Denmark
Pan-cytokeratin AE1/3 1:50 DAKO, Glostrup, Denmark
S-100 protein polyclonal 1:2000 DAKO, Glostrup, Denmark
 P63 4A4 1:5000 Thermo Fisher Scientific, USA
GFAP GA-5 1:200 DCS, Hamburg, Germany
Calponin CALP 1:400 DAKO, Glostrup, Denmark
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Pathologic Findings 
Grossly, the neoplasms were described as white or yellowish nodules, solid, gelatinous 
and also cystic in appearance. Hemorrhage and necrosis was seen in some of the 
lesions. The size range for MECs was 3.5 to 15 cm (mean, 6.7 cm) and for EMCs 1 to 15 
cm (mean, 8.5 cm). In one EMC, the size was unknown. 
 Histologically, most cases demonstrated a (multi)-nodular configuration with 
expansive margins and an incomplete pseudo-capsule. Infiltrative margins were 
focally seen. MECs showed in most of the cases varying growth patterns such as 
trabecular, reticular, nested and solid. A pure trabecular pattern was seen in two 
cases. Six tumors were composed of different cell types, including spindle, epithelioid, 
plasmacytoid and/or clear cells. Round cell morphology associated with clear cells 
was observed in two cases and a pure epithelioid phenotype in two other cases 
(Figure 1). Osteoclast like giant cells were scattered in Cases 1 and 4. All cases exhibited 
moderate to severe nuclear atypia with vesicular or coarse chromatin (Figure 2). 
Prominent nucleoli were conspicuous in seven cases. Mitoses ranged from one to six 
per ten HPF. The matrix was (chondro)myxoid in 8 cases with pseudocystic changes 
in two cases. Five tumors showed stromal hyalinization. Areas of hemorrhage and 












































































































































































































































































































































































































































































































































Figure 1   This case of MEC showed a reticular and cord like pattern of epithelioid 
cells set in a prominent myxoid matrix (Case 5)
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 All EMC cases had focally classical features with strands and cords of small, 
uniform round to spindle-shaped cells set in a prominent myxoid matrix. There were 
round to oval nuclei and limited deeply eosinophilic cytoplasm. The tumor nodules, 
separated by fibrous septa, showed often a peripheral cell condensation. In the 
cellular areas, sheets and nests of tumor cells were present. A trabecular and reticu-
lar-cystic pattern as well as loosely arranged cells occurred variably. The lesional cells 
were epithelioid and/or spindle-shaped and slightly pleomorphic (Figures 3 and 4). 
Case 13 showed increased pleomorphism, cytoplasmic vacuoles, multinucleated giant 
cells and prominent necrosis. In two cases, larger nuclei and prominent nucleoli were 
seen (cases 11, 12). Rhabdoid cytology was observed in Case 12. For all cases, the 
mitotic activity was very low ana did not exceed one mitosis/ten HPF. In the cellular 
areas, the myxoid matrix was scant or even absent. 
 Immunohistochemically, eight of ten (80%) myoepithelial carcinomas were, at 
least focally, positive for pan-keratin and four of seven (57%) for epithelial membrane 
antigen (EMA). The two cases negative for pankeratin expressed EMA. Two of eight 
cases showed nuclear immunoreactivity for p63 (25%). Alpha-smooth muscle actin 
(ASMA) was detected in six of eight (75%) and calponin in four of six cases (67%). A 
focal expression of S100 was seen in five of ten cases (50%). Glial fibrillary acidic 
protein (GFAP), in four cases performed, was negative in all four. In cEMCs, S100 and 
Figure 2   Note the nuclear pleomorphism, more often seen in MEC (Case 3)
Figure 4   Solid and reticular arrangement of slightly polymorphic epitheloid cells in 
a cellular EMC
Figure 3   Monomorphic epithelioid and spindle-shaped cells in a cellular EMC (Case 11)
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EMA were each expressed in two of five cases (40%). One of the mentioned 
S100-positive cases (Case 11) showed a broader pattern of marker expression with 
additional immunoreactivity for p63 (Figure 5), and focally for ASMA and GFAP. 
Pan-keratin was negative in all neoplasms (Table 3).
Figure 5   p63 was positive in one of the cellular EMC cases (Case 11)
Figure 6   NR4A3 rearrangement by FISH showing break-apart signal. This was 
observed in all EMC cases successfully tested
Table 3  Immunohistochemistry
Case Pan-CK EMA p63 ASMA S100 GFAP Calponin
MEC
1 - + - f + - nd +
2 + nd - f + f + - f +
3 f + nd - f + - nd f +
4 - + - f + - - nd
5 f + - nd f+ - nd nd
6 + nd + + - nd nd
7 + + - - f + - -
8 + - nd nd + - +
9 + - - - f+ nd -
10 + + + nd f+ nd nd
8/10 4/7 2/8 6/8 5/10 0/4 4/6
80% 57% 25% 75% 50% 0% 67%
EMC
11 - - + f + f + f+ nd
12 - - - - f + - nd
13 - f+ nd - - - nd
14 - - - - - - nd
15 - f+ - - - - nd
0/5 2/5 1/4 1/5 2/5 1/5
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Discussion
The first myoepithelial tumor of the soft tissue was published by Stout and Gorman in 
1959 in a series of cutaneous lesions.30 In the largest series to date, moderate to 
severe atypia (vesicular or coarse chromatin, prominent, often large nucleoli, or 
nuclear pleomorphism) was determined as indicating malignancy.2 The wide 
morphological and immunohistochemical diversity, presumably a result of the 
plasticity of myoepithelial cells, is the cause of the many differential diagnoses, which 
include most importantly the cellular variant of extraskeletal myxoid chondrosarcoma, 
furthermore are atypical/malignant ossifying fibromyxoid tumor, undifferentiated 
carcinoma, epithelioid MPNST, proximal type epithelioid sarcoma, and in cases with 
round cell morphology, Ewing sarcoma, myxoid/round cell liposarcoma and poorly 
differentiated synovial sarcoma are to be considered, at least in small samples.2-4
 The occurence of myoepithelial tumors at different sites possibly reflects an 
aberrant gene expression pattern during oncogenesis rather than origin from a 
specific cell lineage.3 This is supported by the evidence of EWSR1 rearrangement in a 
subset of benign and malignant myoepithelial tumors of skin, soft tissue, bone and 
visceral locations (lung).25,31 The hitherto identified fusion genes are POU5F1, PBX1 
and ZNF444.23-25 Other more heterogenic genetic changes are also identified 
including recurrent aberrations of chromosome 9.27,32-34 Recently, a pleomorphic 
adenoma gene 1 (PLAG1) rearrangement was discovered in a subset of benign mixed 
tumors of skin and soft tissues (with well-formed ducts). It seems that this genetic 
abnormality excludes EWSR1 rearrangement.35 Whether malignant myoepithelial/
mixed tumors possess similar features remains unresolved as yet.
 When Enzinger designated extraskeletal myxoid chondrosarcoma as a distinct 
entity he already mentioned a resemblance with salivary gland type, mixed tumors of 
deep fascial region of thigh with reference to the report by Dutra in 1960.5,36 
 Classical cases of EMC have a typical histomorphology with uniform small round 
to spindle-shaped cells with deeply eosinophilic cytoplasm. The cells are arranged in 
a delicate network set in a copious myxoid stroma. Cellular variants, representing 
approximately one third of the cases, show greater morphologic heterogeneity, often 
resembling myoepithelial tumors.2,4,5,8,10,11,25,33,37,38 
 Both tumor types share features such as lobular or multinodular architecture, 
variable amounts of myxoid stroma and a reticular growth pattern. The stromal 
component in cellular areas can be poor or even absent. The cells variably epithelioid, 
round and spindle shaped. Rhabdoid cytology may also be present in both. Unlike 
myoepithelial carcinomas, moderate to severe nuclear atypia is much less common in 
cEMC and can therefore be a helpful discriminating sign. This was also a finding in our 
series. Ductular structures and metaplastic cartilage or bone, present in not more 
than 20% of soft tissue myoepithelial tumors, are not a feature of EMC.2-8,10,38-41 
FISH and RT-PCR analysis
In three of nine (33%) MECs, a EWSR1 rearrangement was observed by FISH. One case 
failed for analysis due to poor hybridisation. No tumor showed a NR4A3 rearrangement. 
Aberrations of chromosome 9 were seen in 2 instances. One of them harbored a 
polysomy and one a heterozygous deletion. All EMCs successfully tested (four of five) 
exhibited a NR4A3 rearrangement (Figure 6). One case failed for RT-PCR and 
NR4A3-FISH. Three cases showed a EWSR1 rearrangement by FISH. In one of them a 
fusion of TAF15-NR4A3 was additionally detected by RT-PCR. In Case 15, NR4A3 was 
rearranged (by FISH) but a fusion with EWSR1 or TAF15 was not found (RT-PCR). 
EWSR1-NR4A3 was evident in 1 neoplasm (Table 4).
Table 4  Molecular analyses (FISH*, RT-PCR)
Case EWSR1* NR4A3/cep 9* TAF15-NR4A3 EWSR1-NR4A3
MEC
1 + -
2 + heterozygote deletion chr. 9
3 - -
4 - -
5 -  nd - -
6 + -
7 - -




11 + nd +  -
12 nd nd - +
13 + + x x
14 +  x x x
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Myxoid epithelioid sarcoma: 
a diagnostic challenge. 
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Introduction
In the first description of 62 cases of epithelioid sarcoma (ES) in 1970 by Enzinger, 
extensive extracellular mucinous material was present in five of 15 cases, that had 
been stained for mucopolysaccharides.1 Nevertheless, myxoid stromal change in ES 
was described as a rare occurrence in subsequent studies.2-4
 In contrast to ES, benign or malignant myoepithelial neoplasms of skin and soft 
tissues often show, at least focally, prominent myxoid stroma.5-9 Like ES, cases of 
myoepithelioma tend to occur on the extremities of adolescents and adults and may 
show overlapping morphological features with ES such as a nodular proliferation of 
spindled and epithelioid tumor cells. More rarely, myoepithelioma and ES may occur 
in children.1,7-11 The immunophenotype of myoepitheliomas and ES shares similarities 
with simultaneous expression of epithelial markers and vimentin, although actins are 
expressed more rarely in ES. Discriminating markers for myoepitheliomas are S-100, 
GFAP and calponin, being positive in the majority of cases.6-9 Approximately 50-67% 
of ES are positive for CD34 which is not seen in myoepitheliomas.3,5-9,12-16 Most cases 
of ES (> 80%) show loss of  SMARCB1 protein expression, and this phenomenon is also 
described in a subset of myoepithelial carcinomas.9,16-18 
 In this study we describe six cases, the largest series so far, of the myxoid variant 
of the distal and proximal type ES, and discuss the differential diagnosis, with special 
emphasis on the distinction from benign and malignant myoepithelioma of skin and 
soft tissue.
Material and methods
The cases were retrieved from the files of the Department of Pathology, Radboud 
University Medical Centre Nijmegen (Nijmegen, The Netherlands), of the Dermato-
pathologie Bodensee (Friedrichshafen, Germany) and from the consultation files of 
one of the authors (TM). One case was selected from PALGA, the nationwide network 
and registry of histopathology and cytopathology in the Netherlands. Slides were 
reviewed and the diagnosis of ES was based on histological and immunohistochemical 
criteria according to WHO classification.22 Cases in which 50% or more of the tumor 
area showed myxoid change were included in the study. The specimens had been 
obtained by surgical excision, fixed in 10% buffered formalin, and processed for 
paraffin embedding. Four-µm-thick sections were stained with haematoxylin and 
eosin, and immunohistochemically by the labeled streptavidin-biotin technique using 
commercially available antibodies; appropriate positive and negative controls were 
used in each case. Antibodies, their sources and dilutions are summarized in Table 1. 
Abstract
Epithelioid sarcoma (ES) is a distinct sarcoma-type with a specific morphology and 
immunophenotype. Whereas focal myxoid change does occur, to our knowledge only two 
cases of ES with diffuse myxoid stroma have been reported previously. To characterize 
more clearly the myxoid variant of ES, we describe six additional cases and discuss the 
differential diagnoses.
 Cases were retrieved from the authors’ files and studied histologically, immuno-
histochemically and by molecular methods. The age of the patients, four females and 
two males, ranged from 16 to 74 years (median: 33 years). The neoplasms arose in an 
extremity (two cases), the abdominal wall, groin, perineum and shoulder (one case 
each). Histologically, four cases were of the conventional type, and two were of the 
proximal type and the immunophenotype was typical for ES. The tumor stroma, 
however, revealed prominent myxoid changes, ranging from 50 to 90% (median: 
75%). Only one of the proximal type ES showed a SMARCB1 mutation, whereas the 
other tumors showed no mutation. 
 The myxoid variant of ES represents a diagnostic challenge and may be confused 
with other myxoid benign and malignant neoplasms. The main differential diagnosis 
is myoepithelioma of the skin and soft tissue.
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 Microscopically, in all tumors a (multi)nodular growth with infiltrative margins 
were seen (Figure 1). The tumor cells were arranged in nests and cords, with the 
myxoid stromal background. A reticular growth pattern was observed in three cases 
(two of the distal type and one of the proximal type) (Figures 2 and 3). Classical solid 
areas were seen in all cases (Figures 1 and 4). The epithelioid tumor cells contained 
abundant eosinophilic cytoplasm and round, vesicular nuclei. Prominent nucleoli 
were seen variably. In all four cases of the distal type, scattered spindle-shaped tumor 
cells were noted. In two cases plasmocytoid cells were also recognized (Figure 5). 
Centrally the tumors showed hyalinization (4 cases) and/or necrosis (3 cases). The 
two cases of proximal type were composed of larger epithelioid and rhabdoid tumor 
cells (Figures 3 and 4). 
 Necrosis was seen in one of the proximal type, and in all but one of the distal ES. 
An inflammatory reaction was more prominent in the cases of the distal type. The 
mitotic rate ranged from 12 to 24 mitoses per 2mm2 in the cases of the proximal type 
and from 3 to 11 mitoses per 2mm2 in the cases of the distal type. 
 Two cases were 90% myxoid, and one case each showed 80% and 70% myxoid 
stromal change, whereas in two cases 50% myxoid areas were observed (Table 2). 
 Immunohistochemically, tumor cells in all cases stained strongly positive for 
vimentin, pan-cytokeratin (Figure 6) and EMA. In addition, CD34 was positive in two 
cases (Figure 7), and expression of ASMA was present focally in two cases. Weak and 
 Genomic DNA was extracted from the paraffin embedded specimens of all six cases 
by use of commercially available kits (Qiagen, Venlo, The Netherlands). SMARCB1 mutation 
analysis was performed as described previously.23 The clinical information were obtained 
from the referring clinicians and pathologists.
Results
Clinical findings 
Details are summarized in Table 2. The neoplasms arose in four females and two 
males. The age of the patients ranged from 16 to 74 years (median: 33 years). Anatomic 
sites included the extremities (two cases), the abdominal wall, perineum, groin, 
shoulder (one case each). The patients were treated by wide excision or reexcision 
with tumor free margins in all cases. Local recurrences were seen in three cases, two 
of the distal and one of the proximal type. The two recurring distal type neoplasms 
showed two and four recurrences respectively, and subsequently developed lymph 
node metastases.
Pathological features
The size of the neoplasms ranged from 1.0 to 4.0 cm (median: 1.8 cm). Sites of involvement 
were the dermis and subcutis of the abdominal wall, schoulder and hand and soft tissue 
of the lower leg (distal type), and subcutis of the groin, and vulva (proximal type).
Table 1  Panel of antibodies used in this study
Antigen Clone Dilution Source
Vimentin V9 1:150 Dako
Pan-cytokeratin MNF116 1:100 Dako
Pan-cytokeratin AE1/3 1:50 Dako
CD34 HPCA-1 1:100 Becton & Dickinson
SMA 1A4 1:300 Dako
BAF 47 25 1:250 BD Transduction Laboratories
S-100 Polyclonal 1:2000 Dako
Calponin CALP1 1:400 Dako
EMA E29 1:3000 Dako
P63 4A4 1:400 Dako
GFAP GA-5 1:200 Biogenix




















































1 M 48 abdominal wall 
(dermis, subcutis)
distal 1.6 80 2 lymph node groin
2 F 22 vulva (subcutis) proximal 1.5 70 NA NA
3 F 16 lower leg
(soft tissue)
distal 2.0 90 NA NA
4 M 74 shoulder,  
(dermis, subcutis)
distal 4.0 50 no No
5 F 41 hand (subcutis) distal 1.0 50 4 lymph nodes axilla
6 F 25 groin (subcutis) proximal 4.0 90 1 NA
570 71
CHAPTER 5 MYXOID EPITHELIOID SARCOMA
Figure 3   This neoplasm of the proximal type is composed of nests and cords of 
enlarged tumour cells with rhabdoid features (case 2)
Figure 1   Classical features in one of the distal type ES (case 1) with nodular 
architecture and inflammatory reaction; myxoid background is also seen
Figure 4   Predominantly solid areas in a proximal type ES (case 6)Figure 2   Epithelioid and spindle-shaped tumour cells in case 3 are arranged in 
cords given a reticular growth pattern. Note the prominent myxoid stroma
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Figure 7   CD34 positivity was observed in two cases (case 6)Figure 5   Epithelioid and spindle tumour cells set in a prominent myxoid stroma; 
scattered plasmocytoid cells are also present (case 4)
Figure 8   All cases showed loss of SMARCB1 protein expression (case 6)Figure 6   Pan-cytokeratin expression was a characteristic feature of all cases (case 6)
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 The reported neoplasms, two of the proximal and four of the distal type, were 
localized in the dermis, subcutis and deep soft tissues, and showed classical morphological 
and immunohistochemical features of ES. In addition, prominent myxoid stromal 
changes were seen in all cases and tumor cells were often arranged in cords and 
nests; a somewhat reticular architecture was seen in three cases. Our findings are 
comparable to those described earlier for two distal type myxoid ES.25
 All cases were negative for SMARCB1 protein expression. This confirms recently 
published studies, showing loss of SMARCB1 protein expression in more than 80% of 
cases of ES.16-18,20 Only one of our proximal-type ES showed a SMARCB1 mutation, 
whereas the other tumours had no mutation. The low frequency of mutations 
affecting the SMARCB1 gene in our series of ES is comparable to others and suggests 
that the expression of  SMARCB1 in this tumor type is down-regulated by alternative 
mechanisms, such as epigenetic modification.18,20
 The main differential diagnosis of myxoid ES is myoepithelioma of skin and soft 
tissues. These neoplasms also arise predominantly in the extremities of (young) adults and 
children. Because of the plasticity of myoepithelial cells, they show heterogeneous 
morphological features, consisting of spindled, epithelioid,  plasmocytoid and clear 
cells often set in a (chondro)myxoid or collagenous/hyalinized stroma.5-8 Hence, 
there is morphological overlap with myxoid ES, showing predominantly epithelioid 
and spindle shaped cells. Ductal structures in myoepitheliomas are of help in the 
distinction of both entities. This feature was not observed in our cases. Futhermore, 
all of our cases showed also classical morphology of ES in at least 10% of tumor. The 
distal type cases in our series showed a granulomatous appearance and necrosis. 
Moreover, none of the tumors of our series expressed S-100 protein, which was seen 
in 87% to 93% of myoepithelial neoplasms.7,8 The presence of pankeratin and EMA 
was 100% in our cases as expected in ES, while AE1/AE3 is positive in only 77% and 
EMA in only 63% of myoepithelial neoplasms.7 Smaller series showed similar results.8,9 
The focal staining for ASMA in two and calponin among three of our cases was very 
weak and not comparable to that is seen in myoepithelial neoplasms.5-9 Two of our 
cases showed discriminating positivity for CD34, which concurs with its reported 
positivity in approximately 50 % of ES.3,13, 14,16 We observed negative staining results 
for GFAP and p63, analogous to the results of others, whereas positivity has been 
described in approximately 46 - 100% and 7 - 27% of myoepithelial neoplasms, 
respectively.6-9,15
 As in ES, SMARCB1 protein expression in myoepithelial carcinomas may be absent, 
as has been shown recently,9,17 the genetic background of which is still unknown.
 Epithelioid haemangioendothelioma (EHE) of skin and soft tissues may also enter 
the differential diagnosis of myxoid ES. This distinct malignant vascular tumor, 
occurring most commonly in middle-aged patients, has a wide range of localization. 
Tumors of the skin are very rare and both single and multiple lesions have been 
focal positivity of calponin was seen in three cases. SMARCB1 (BAF47) was absent in 
all six cases (Figure 8). None of the neoplasms expressed S-100 protein, GFAP, or p63 
(Table 3).
SMARCB1 gene status
All tumors were investigated for the presence of mutations of the SMARCB1 gene. In 
one tumor a mutation in exon 6 was recognized, which we have reported previously.20 
In this case of proximal type, localized in the vulva, we identified a c.769C>T transition 
resulting in the generation of an in-frame stopcodon (CAG->TAG, p.Q257X) in the 
transcript and premature termination of SMARCB1INI1 protein synthesis. In 
accordance with the two-hit model for tumor genesis, we noted considerable loss of 
the wild-type copy of this gene in the tumor. None of the other cases had mutation of 
SMARCB1.
Discussion
Myxoid tumors of soft tissue encompass a heterogenous group of lesions characterized 
by a marked abundance of extracellular mucoid (myxoid) matrix. Thus, they demonstrate 
significant variability in their biological behavior thus including indolent tumors, 
tumors with a tendency to recur locally but not metastasize, and malignant tumors.24
Although in classical ES myxoid stromal changes are well known, only two cases of  ES 
with diffuse myxoid background have been described so far.1,4,14,25
 We report an additional series of six cases of myxoid ES and discuss their 
morphological, immunohistochemical and molecular features, and the differential 
diagnosis to other benign and malignant neoplasms of skin and soft tissues.































1 + + + + - - - - - -
2 + + - + - - - - - -
3 + + - + + focal - - - - + focal,weak
4 + + - + - - - - - + focal,weak
5 + + - + + focal - - - - + focal,weak
6 + + + + - - - - - -
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described; the last is seen typically in progressive ES. Histologically, EHE shows a 
(multi) nodular architecture and is composed of short strands, cords or small clusters 
of epithelioid to slightly spindled cells with an eosinophilic cytoplasm and vesicular 
nuclei. In some cases, intracytoplasmatic vacuoles, usually a prominent feature in 
EHE, could be in some cases very subtle and are recognized occasionally in ES due to 
lipid droplets. The typically myxohyaline stroma shows, variably, haemorrhage and/
or haemosiderin deposits. Discriminating immunohistochemical features are 
positivity for specific endothelial markers, as CD31 (with a strong membranous 
reaction) and Fli-1 (with nuclear staining) in EHE, whereas EMA, usually positive in ES, 
is rarely detected in EHE. Cytokeratin and CD34, variably positive in both tumors, are 
not useful in the differential diagnosis.26-29
 Another differential diagnosis of ES represents extraskeletal myxoid chondrosarcoma 
(EMC). EMC typically shows a multinodular growth pattern with interlacing cords of 
round or plump-spindled tumor cells set in a chondomyxoid background. In contrast 
to ES, the cells of EMC are less epithelioid and the architecture is more homogeneous. 
A cellular high grade variant and rhabdoid features is also described, showing a 
greater degree of morphological overlap especially with proximal type ES.30,31 The 
rhabdoid features in EMC were associated with loss of SMARCB1/INI1 expression and 
partly with genetic alteration in SMARCB1/INI.31 If immunohistochemistry is required 
for a definitive diagnosis, S-100 is expressed in a minority of cases, and epithelial and 
myogenic markers are usually absent.7,32 Typical translocations, t(9;22) (q22;q12), 
t(9;17) (q22;q11), and t(9;15) (q22;q21), provide proof proof of this sarcoma.33,34
 Recently, an epithelioid variant of myxofibrosarcoma has been described composed 
mainly of epithelioid fibroblastic cells set in a myxoid stroma. In addition pseudolipo-
blasts and numerous elongated, curvilinear blood vessels are present, mostly seen in 
the hypocellular myxoid areas.35 This tumor usually arises in elderly patients, lacks 
the expression of epithelial markers and does not show loss of SMARCB1 protein 
expression. 
 In summary myxoid ES represents a rare variant of ES and prominent myxoid 
stromal changes are seen in both the distal and proximal types. Correct diagnosis can 
be problematic, particularly in small biopsy specimens, and cases of benign and 
malignant myoepithelioma, extraskeletal myxoid chondrosarcoma and epithelioid 
myxofibrosarcoma have to be distinguished from myxoid ES.
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Presence of C11orf95-MKL2 fusion  
is a consistent finding in chondroid  




CHAPTER 6 C11ORF95-MKL2 IN CHONDROID LIPOMAS
Introduction
Chondroid lipomas are rare, often deep-seated, benign lipogenic tumors occurring 
mainly in the extremities and limb girdles of adults. A female preponderance has 
been reported.1
 The histomorphological hallmark is an admixture of adipocytes, lipoblasts, hibernoma- 
like cells and chondroblast-like cells embedded in a myxohyaline chondroid matrix.1 
 A characteristic chromosomal abnormality has been demonstrated and recently, 
the corresponding fusion gene was detected in three of three cases.2-5
 The use of minimally invasive biopsies has become increasingly common, and 
molecular genetic testing can serve as a useful diagnostic adjunct. Therefore, it seemed 
appropriate to look for this fusion gene in a larger cohort.
Material and methods
The cases were retrieved from the authors’ (referral) files, and clinical details and 
follow-up were obtained from the referring physicians. Details of two of the cases 
have been published previously.6,7 Tissue was fixed in 4% buffered formalin, routinely 
processed and embedded in paraffin; 2-4 µm thick sections were stained with hema- 
toxylin and eosin and immunohistochemically by the labelled streptavidin biotin 
technique using commercially available antibodies as listed in Table 1. Appropriate positive 
and negative controls were used throughout.
Translocation-specific RT-PCR
cDNA synthesis was performed in a 24 ul reaction mixture containing 1 ug of RNA, 1 
ug of random hexamers (Promega, Madison, WI, USA) and 20 nmol dNTPs (Invitrogen, 
Carlsbad, CA, USA) and heated at 65 °C for 5 min. Next 2 ul of RNasin (Promega), 8 ul 
of 5x first strand buffer (Invitrogen), 4 ul of 0.1 M dithiothreitol (Invitrogen) and 2 ul of 
Superscript II reverse transcriptase (Invitrogen) were added and the samples were 
heated as follows: 10 min at 20 °C, 60 min at 42 °C and 3 min at 95 °C. cDNA was 
stored at -20 °C.
 Translocation-specific C11orf95-MKL2 fusion products, as described by Huang et al5 
were detected using primers targeting C11orf95 (5’ GAGTACCTGATGGACTACGAC 3’) 
and MKL2 (5’ GACCCCTTAACTTCAGTTCTG 3’). 
 PCR was carried out in duplicate in a PTC 200 Thermal Cycler (MJ Research, 
Waltham, MA, USA) starting with 10 min at 95 °C and followed by 38 cycles of 
denaturation at 95 °C for 30 s, annealing at 58 °C for 30 s and extension at 72°C for 
60 s, with a final extension at 72°C for 7 min and then cooling down for 5 min at 20°C. 
PCR products were analyzed by 2% agarose gel electrophoresis.
Abstract
Chondroid lipomas are benign adipose tissue tumors. Their rarity and peculiar 
morphology can lead to misinterpretation, especially in small biopsies. Based on a 
recurrent translocation t(11;16)(q13;p13), the C11orf95-MKL2 fusion gene has been 
found in a few cases. Therefore, it seemed appropriate to look for this fusion gene 
in a larger cohort.
 We describe eight further cases from four females and four males with an age 
range of 21-81 years (median, 49 years). The tumors were situated in the lower arm 
(three), lower leg (two), thigh (one), back (one), and head (one); seven lesions were 
deep-seated and one was located subcutaneously. Sizes ranged from 3 to 12 cm 
(median, 6.3 cm). All patients were treated by simple excision, and follow-up, available 
for six patients (range 2 months – 12 years; median 15 months), demonstrated 
recurrence in one case. Histologically, the circumscribed and lobulated tumors 
showed a variable composition of adipocytes, lipoblasts, hibernoma-like cells and 
chondroblast-like cells embedded in a chondroid matrix.
 Immunohistochemistry, performed in four cases, revealed positivity for S-100 and 
pancytokeratin in two of three neoplasms stained for each marker. A C11orf95-MKL2 
fusion gene was shown by RT-PCR analysis in seven of the eight cases. 
 Molecular analysis can be used to support the diagnosis of chondroid lipoma, 
especially in small samples. This may be helpful in planning treatment when the 
differential diagnosis includes malignant lesions.
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Results
Clinical data are presented in Table 2. The eight lesions were from four females and 
four males, with an age range of 21-81 years (median, 49 years). The tumors were 
situated in the lower arm (three), lower leg (two), thigh (one), back (one), and head 
(one). Seven neoplasms were deep seated and one was located subcutaneously. The 
size ranged from 3 to 12 cm (median, 6.3 cm). Follow-up available for 6 patients (2 
months – 12 years; median interval, 15 months) showed a recurrence in one case (case 
5) after 5 years. All other patients were cured by simple excision. The tumors appeared 
grossly well circumscribed and encapsulated, with a lobulated and yellowish cut 
surface (Figure 1). 
 Microscopy confirmed the lesions to be well circumscribed and encapsulated. 
In several cases the presence of septa resulted in a multinodular appearance. The 
adipocytic component ranged from 10% to 70% and was admixed with hibernoma-like 
cells, lipoblasts and chondroblast-like cells. The eosinophilic cells showed arrangement 
in sheets, nests and cords. The nuclei varied in shape from oval to reniform and were 
placed centrally or peripherally, with some variation in nuclear size in four cases. 
Classical lipoblasts had indented nuclei. Prominent nucleoli and mitotic figures were 
not seen. The myxohyaline matrix was prominent in two cases. A striking feature in all 
cases was a prominent vasculature with thick- and thin-walled vessels. Some of the 
vessels were hyalinized (Figure 2). 
 Immunohistochemistry was performed on four tumors. Two of three were 
positive for S-100. One (one of one) was positive with the pan-cytokeratin antibody 
MNF 116 (Figure 3) and another (one of two) with pan-cytokeratin AE1/3. Immuno-
histochemistry for epithelial membrane antigen (EMA) and smooth muscle actin was 
performed in one case each, with negative results (Table 3).
 By RT-PCR, we found C11orf95-MKL2 fusion in seven of eight cases (Table 3). All 
seven cases harboured a translocation resulting in a fusion between exon 5 of 
C11orf95 and exon 9 of MKL2. Six cases had the same fusion-product as described by 
Table 1  Details of used immunohistochemical antibodies
Antibody Clone Dilution Source
ASMA 1A4 1:500 DAKO, Glostrup, Denmark
EMA Mc5 1:400 BioGenex, San Ramon, USA
Pan-cytokeratin MNF116 1:500 DAKO, Glostrup, Denmark
Pan-cytokeratin AE1/3 1:50 DAKO, Glostrup, Denmark
S-100 polyclonal 1:2000 DAKO, Glostrup, Denmark
Figure 1   Case 1: grossly, the tumour looks like a usual lipoma (with a multilobular 
pattern)
Figure 2   The tumours show an admixture of adipocytes, lipoblasts, hibernoma-like 
cells and chondroblast-like cells set in a myxohyaline, chondroid matrix
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Huang et al.5 In one case (Case 1), an alternative breakpoint in C11orf95 was detected 
(Figure 4). The PCR product was 39 base-pairs smaller. 
 Two hibernomas, of a 25 year old female and a 59 year old male, both located in 
the upper leg were used as controls and were negative for the gene fusion.
Figure 3   Pan-keratin may be expressed in this tumor type (Case 6)
Figure 4   The sequence of RT-PCR product shows a fusion between exon 5 of 
C11orf95 and exon 9 of MKL2 in the chimeric transcript in 7/8 cases
Table 2  Clinical data
Case Age/Sex Localization Size (cm) Follow-up
1 41 y/f lower arm, deep 4.5 2 mos, NED
2 21 y/f lower leg, deep 4.5 17 mos, NED
3 38 y/f thigh, deep 12 12 ys, NED
4 56 y/m back deep 3 7 mos, NED
5 57 y/m lower arm, sc 8 12 ys, 1 rec after 5ys
6 34 y/m lower arm, deep NA 12 mos, NED
7 81 y/m infratemporal fossa, deep NA NA
8 69 y/f calf, deep 11.4 NA
Y, years; f, female; m, male; NA, information not available; sc, subcutaneous; rec, recurrence; mos, 
months; ys, years; NED, no evidence of disease
Table 3  Immunohistochemical and molecular data
Case S-100 Pan-CK EMA ASMA C11orf95-MKL2  
(exon 5 - exon 9)
1 - - nd - +
2 + nd nd nd +
3 nd nd nd nd +
4 nd nd nd nd +
5 nd nd nd nd +
6 nd + nd nd +
7 + + - nd -
8 nd nd nd nd +
+, positive; -, negative; nd, not done
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 Although occurring very infrequently, chordoma periphericum is one of the 
differential diagnoses. The histomorphology is similar to axial chordomas, with 
nuclear atypia of the clear to eosinophilic physaliferous cells. A lipogenic component 
does not exist. Brachyury is the key immunohistochemical marker providing evidence 
for notochordal differentiation.20
 Hibernoma consists of brown fat cells with granular, multivacuolated cytoplasm 
and mature adipocytes in varying amounts. Although, myxoid changes can occur in all 
lipomatous tumors, a prominent chondromyxoid matrix is not typical for hibernoma, 
and chondroblast-like cells are absent.12,21,22 Breakpoints in 11q13.5 near GARP and 
deletions of various genes of 11q13 were detected.8,10 But CIIorf95 is not involved, as 
demonstrated by FISH5 and, in our two cases, by RT-PCR. 
 Lipoblastoma is an adipose lesion of infancy and early childhood with nearly 90% 
occurring before 3 years of age.22 It has been rarely reported in adolescents and 
young adults.22,23 These lobulated tumors are composed of fat cells with varying 
degrees of differentiation, including primitive cells or prelipoblasts, lipoblasts and 
adipocytes. Hibernoma-like cells can occur in contrast to chondroid cells. Myxoid 
stroma may be prominent in these lesions and the fibrous septa contain numerous 
capillaries.6,22-24 Genetically, most lipoblastomas show a rearrangement of PLAG1 
located on chromosome 8q12 and/or possess extra copies of the same chromosome.22,23 
Alternatively, HMGA2 can be rearranged.25
 Metaplastic cartilage has been described in a variety of lipogenic tumors, 
such as chondrolipoma, lipoblastoma, myxoid liposarcoma and dedifferentiated 
liposarcoma.1,6,24,26 This supports the notion of overlapping pathways in lipo- and 
chondrogenesis;5,27 therefore, it is not surprising that lipo- and chondrogenic features 
are also discussed in chondroid lipomas.5,26 
 Recurrent chromosome rearrangements, in particular translocations, are strongly 
associated with distinct tumor entities.28 However, overlap in different tumor types is 
well known.12,29 There is compelling evidence that they represent an initial event in 
oncogenesis.28
 The treatment of chondroid lipoma is simple excision and recurrence has been 
rarely reported.30 In our series, only one patient had a recurrence, after 5 years. This 
corroborates the benign nature of the lesion.1,6
 In summary, chondroid lipoma is a very rare, often deep-seated benign lipogenic 
tumor with chondroid features and a consistent molecular abnormality: the detection 
of CIIorf95-MKL2 can provide diagnostic confirmation.
Discussion 
Adipocytic tumors represent the largest group of soft tissue tumors in general.1,6 
They have been studied extensively by cytogenetic analysis, and the first reported 
consistent karyotypic abnormality has been discovered in lipomas.8
 Recurrent involvement of 11q13 was found in the karyotypic alterations of lipoma, 
hibernoma and chondroid lipoma.2-5,9-13 Chondroid lipoma shows a consistent t(11;16)
(q13;p13) translocation resulting in the fusion oncogene C11orf95-MKL2.2-5 Six of our 
cases harboured the previously described breakpoint regions5 and, in one case, an 
alternative breakpoint in C11orf95 was detected generating a fusion-product that 
involved the same exons. Interestingly, the structure of the genes as illustrated by 
Huang et al.5 differs from that of the Reference Sequence (RefSeq) database genes, 
and it is therefore difficult to annotate these fusion-products accurately. The MKL2 
protein is known to be involved in chromatin remodeling and transcription. The 
function of C11orf95 is as yet unknown.5 
 As indicated by our series, C11orf95-MKL2 is a consistent finding in chondroid 
lipomas and can be of diagnostically value, especially in small samples, because of the 
therapeutic consequences when malignant lesions are included in the differential 
diagnoses.
 When Meis and Enzinger first described chondroid lipoma1 they underscored the 
resemblance to myxoid liposaroma (MLS) and extraskeletal myxoid chondrosarcoma 
(EMC). Both of these entities share the myxohyaline chondroid matrix, but neither 
has the prominent vasculature varying from thick-walled to thin-walled and cavernous 
blood vessels. The delicate plexiform capillaries, characteristic for MLS, are absent in 
chondroid lipoma, as are the typical primitive cells.1 Cords and nests of small chond-
roblast-like eosinophilic cells are an overlapping feature with EMC. Although some 
vacuolated cells can occur in EMC, there is no adipocytic/lipoblastic component. 
However, extensive myxoid change can obscure the latter.1 S-100 immunohistochem-
istry can be positive in all three tumor types and is therefore of little value. Both 
sarcomas possess a specific genetic abnormality with a fusion gene involving NR4A3 
in EMC and DDIT3 in MLS.12
 Myoepithelioma, especially with ‘parachordoma’- like appearance, enters the 
differential diagnosis.1 In addition to the architecture and cytomorphology (nest- and 
cord-like arrangement of clear to eosinophilic cells), the myxohyaline chondroid 
matrix and positivity for S-100 and keratin can cause confusion with chondroid 
lipomas. In this context, the heterogeneous composition of myoepithelial cells, 
sometimes with tubuloductal structures, stronger expression of keratins and/or EMA 
and the absence of lipoblasts, are discriminating signs. Conversly, adipocytes can be 
present in myoepithelial tumors.14-17 There is a distinct genetic background with 
EWSR1 or PLAG1  rearrangements in a subset of cases.18,19 
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Introduction
Cellular angiofibroma, first described in 1997 by Nucci et al, is an uncommon benign 
mesenchymal tumor occurring mainly in the genital region of both genders.1-3 
Extragenital localisations are also known; however, most of all lesions are assigned to 
the pelvic area.1-7 They are commonly well-circumscribed, localized in the superficial 
soft tissue and characterized by bland spindle-shaped cells arranged without any 
pattern in a stroma with wispy collagen and numerous small- to medium-sized thick 
walled vessels.1-3
 More recently, atypical features and sarcomatous transformation of cellular 
angiofibroma have been reported. Whereas in some cases, areas of pleomorphic 
spindle cells were examined, others contained a well-differentiated liposarcoma or a 
pleomorphic liposarcoma component, but in neither of these patients a poor outcome 
was present.3,6,8
 The histomorphological and, to a lesser extent, immunohistochemical overlap of 
cellular angiofibroma with spindle cell lipoma and mammary-type myofibroblastoma 
suggested a possible link among them.1-3,9-11 Subsequently, a monoallelic loss of RB1 
and FOXO1, located on 13q14 was found in some of these tumor types supporting the 
notion that they may belong to a spectrum.12-16
 We report on 25 additional cases of CAF to widen the clinicopathologic features 
with an additional morphologically sarcomatous transformed case, and underpin the 
genetic relationship with mammary-type myofibroblastoma and spindle cell lipoma. 
Materials and methods
The cases were retrieved from the authors’ referral files, and clinical details and 
follow-up were obtained from the referring pathologists (see acknowledgement). In 
all cases, the tissue was fixed in 4% buffered formalin, routinely processed, and 
embedded in paraffin; 2-4 µm thick sections were stained with hematoxylin and eosin 
and immunohistochemically by the labelled Streptavidin Biotin technique using 
commercially available antibodies listed in Table 1. Antigen retrieval was performed 
for all of them. Appropriate positive and negative controls were used throughout.
 FISH-analysis for the detection of RB1, located on 13q14.2, was performed in 
seven cases with a direct spectrum orange labelled probe (Abbott, Bergisch Gladbach, 
Germany) on 3 µm sections of formalin-fixed, paraffin-embedded tissue after baking 
at 65°C for 16 hours, deparaffinization with xylene and rehydration with ethanol. All 
tissue sections were pre-treated with a 30% solution of Oncor pre-treatment solution 
and digested with Proteinase K following the instructions of the suppliers (Q-Biogene, 
Heidelberg, Germany). Digestion times were optimized on a case-by-case basis. After 
Abstract
Cellular angiofibroma represents a rare benign mesenchymal tumor, occurring mainly 
in the superficial soft tissue of the genital region. The involvement of 13q14 in some 
cases confirmed the morphologic suggested link with spindle cell lipoma and 
mammary-type myofibroblastoma. We analysed the clinicopathologic and immuno-
histochemical features of 25 cases, and performed in a number of cases additional 
molecular studies. There were 17 female and 8 male patients (age ranged from 27 to 
83 years); females tended to be younger. A marked predilection for the vulva (n=13) 
was observed, and neoplasms in males were predominantly located in the inguinal 
region (n=4), and one case each in the scrotum, perianal, the knee, and the upper 
eyelid. The tumors arose most commonly in the superficial soft tissue and were well 
circumscribed in all but two cases. The tumor size ranged from 1 cm to 9 cm. All 
lesions were composed of spindle-shaped cells associated with numerous small- to 
medium-sized blood vessels, however a broad morphologic variation with foci of 
lipogenic differentiation in 9 cases and sarcomatous transformation in one case was 
found. By immunohistochemistry, 11 out of 22 cases expressed CD34. A focal reaction 
for α-smooth muscle actin was observed in 9 out of 22 cases, and two cases each 
stained weak and focally positive for epithelial membrane antigen and CD99. In all 7 
cases tested, a monoallelic deletion of RB1 was detected by FISH-analysis. Follow-up, 
available in 14 patients, showed neither local recurrence nor metastasis. In conclusion, 
we affirm the link between cellular angiofibroma, spindle cell lipoma and mammary- 
type myofibroblastoma, showing a spectrum of one entity with morphological variations 
dependent on anatomic location.
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local excision. Complete excision was reached in 13 cases and re-excision with 
subsequent tumor free margins was performed in one case (Case 2). Marginal excision 
was verified in four cases and positive margins were reported in seven cases. The 
resection status was not known for Case 21.
a second rehydration step, the probes were applied to the sections and the covered 
slides were sealed with rubber cement, heat-denatured and hybridised at 37°C for 16 
hours. One positive (spindle cell lipoma) and one negative control (normal tissue) 
were included in each FISH-series. 
 After stringent washing with 50 % formamide in 2xSSC and treating with FITC 
anti-DIG in case of the indirectly labelled probes, the sections were counterstained 
with DAPI II in mounting medium (125 ng/ml, Abbott, Bergisch Gladbach, Germany) 
and visualized under a Zeiss Axioplan 2 microscope using a HBO103 lamp and the 
appropriate filters for three fluorescence dyes. 
Results
Clinical Findings
Clinical details are summarized in Table 2. Briefly, the neoplasms arose in 17 female 
and 8 male patients. The age range was 27-83 years (mean: 52 years; median: 50 
years). Women tended to be younger (age range 27 – 63 years; mean: 47 years; 
median: 47 years) than men (age range 32 – 83 years; mean: 63 years, median: 67 
years). Tumors arising in female patients were predominantly seen in the vulva (n=13). 
Four of them were assigned to the labia majora and one to the clitoris. One case each 
was located in the vaginal introitus, vaginal fornix, perineum, and the knee. Lesions in 
male patients were seen in the inguinal region (n=4), the scrotum (n=1), in the perianal 
region (n=1), the knee (n=1) and the upper eyelid (n=1). All patients underwent simple 
Table 1  Details of used immunohistochemical antibodies
Antibody Clone Dilution Source
ASMA 1A4 1:500 DAKO
Desmin D33 1:200 DAKO
CD117 polyclonal 1:100 DAKO
EMA Mc5 1:400 BioGenex, San Ramon, USA
CD34 HPCA-1 1:100 BD Biosciences, San Jose, USA
Pancytokeratin MNF116 1:500 DAKO
S-100 protein polyclonal 1:2000 DAKO
h-Caldesmon h-CD 1:200 DAKO
CD31 JC70A 1:100 DAKO
CD99 12E7 1:500 DAKO
Table 2  Clinical data of 25 cases of cellular angiofibroma
Case Sex/Age Site Size (cm) Treatment Follow-Up (mos)
1 m/48 scrotum 9 R0 110, NER
2 f/41 perineal 3 R0 NA
3 m/75 groin 6.5 R0 48, NER
4 f/39 vaginal introitus 1 R1 75, NER
5 f/50 vulva 3 R1 55, NER
6 f/51 labium majus 2.7 ME 66, NER
7 f/44 labium majus 2.3 R0 NA
8 f/50 vulva 4 R2 NA
9 f/63 knee lateral 4 R0 45, NER
10 f/48 vulva 8.5 R0 NA
11 f/42 vulva 2.2 R0 NA
12 f/63 clitoris 2.5 R1 38, NER
13 f/27 labium majus 8 ME NA
14 f/42 vulva 1.7 R0 30, NER
15 f/46 labium majus 3 ME NA
16 m/83 inguinal canal 2 R0 NA
17 f/55 vulva 2.3 R0 12, NER
18 m/77 inguinal canal 4.5 R0 NA
19 m/56 inguinal canal 3 R0 6, NER
20 m/77 knee 5.1 R0 11, NER
21 f/57 vulva 4.5 RX 6, NER
22 f/47 vulva 1.5 R1 NA
23 m/32 upper eyelid 1.2 R1 6, NER
24 m/59 perianal 8 R1 7, NER
25 f/39 vaginal fornix 9 ME recently
m, male; f, female; R0, complete excision; ME, marginal excision; R1, local excision with histological 
positive margins; R2, local excision with macroscopically positive margins; RX, local excision, margins 
not known 
NA, information not available; NER, no evidence of recurrence
798 99
CHAPTER 7 CELLULAR ANGIOFIBROMA
Follow-up, available for 14 patients, ranged from 6 to 110 months (mean: 37 months; 
median: 34 months). It was unremarkable for all patients. Case 5 most likely represents 
a relapse of an 11 years earlier excised tumor. 
 Given clinical diagnoses were (Bartholin) cyst, polyp, myoma, atheroma, pilomatricoma 
or lacrimal gland carcinoma. The last two diagnoses were assigned to the tumor in the 
upper eyelid.
Pathologic Findings 
Grossly, the neoplasms were described as white or yellowish nodules, mostly solid 
and partly gelatinous or cystic in appearance. Three tumors were recorded as 
polypoid lesions (Case 11, 12, 25). The size ranged from 1cm to 9 cm (mean: 4.1 cm). 
Tumors in women inclined to be smaller (range: 1 cm – 9 cm; mean: 3.7 cm) than in 
men (range: 1.2 cm – 9 cm; mean: 4.9 cm). 
 Histologically, most lesions were found in superficial soft tissue (n=21) and all but 
two were well circumscribed. Nine tumors were at least partly encapsulated. An 
infiltrative growth was seen in Case 5 and 21. The first was located in deep soft tissue 
while the second showed features of sarcomatous transformation (see below). Three 
vulvar and one vaginal lesion were superficially located and showed an exophytic 
growth, one of them (Case 10) was ulcerated. In 11 cases, a multinodular growth with 
incomplete fibrous septa was noted. The spindle-shaped tumor cells were arranged 
haphazardly and showed organisation partly in short fascicles in four cases. They had 
bland, oval to fusiform and sometimes tapering nuclei. The cytoplasm was ill-defined, 
pale eosinophilic and had, if recognizable, bipolar processes (Figure 1). Nuclear 
grooves and intranuclear inclusions were commonly observed. In three cases (Cases 
6, 7, 11), focal mild nuclear atypia with slightly enlarged nuclei was recognizable, and 
furthermore, in Case 11 some multinucleated cells were detected (Figure 2). Six cases 
featured mitotic figures, ranging from 1 to 3 mitoses per 10 high-power fields. A 
transformation from typical areas of CAF into cellular not well-delineated nodules 
composed of enlarged, highly pleomorphic and multinucleated cells with prominent 
nuclear atypia and atypical mitoses was present in Case 21 (Figure 3-5). Thus, this part 
of the tumor has morphological features of malignancy.
 All tumors contained wispy collagen; additionally, thicker collagen bundles were 
focally present in six cases. The vascular component, prominent in all lesions, 
consisted of small to medium sized vessels with mostly hyalinized walls (Figure 1). 
A hemangiopericytoma-like vascular pattern was observed in three cases (Cases 16, 
19, 21) (Figure 6). Edematous changes of vessels due to chronic inflammation were 
seen in four cases and vascular thrombotic obliteration was observed in one case. 
Nine cases (36%) included mature adipocytes, predominantly in peripheral areas, 
ranging from 1 - 30 % of the analysed tumor area. Pseudovascular spaces filled with 
proteinaceous fluid were seen in three cases and microcystic changes in four cases 
Figure 1   Typical features of CAF showing loosely arranged spindle cell lipoma like 
cells and a prominent vasculature with thick vessel walls. There is a finely 
collagenous background (Case 3)
Figure 2   Mild nuclear atypia with slightly enlarged nuclei and multinucleated cells 
found in Case 11
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Figure 5   Pleomorphic tumor cells and atypical mitotic figures of the malignant 
areas of Case 21
Figure 3   The sarcomatous transformed component in Case 21 was not well 
circumscribed and included mature adipocytes
Figure 6   Case 16 shows hemangiopericytoma like vessels and focal inclusion of 
adipocytes; broad collagen deposits are also seen
Figure 4   There are pleomorphic nuclei and a typical pattern of CAF with prominent 
hyalinized vessels (Case 21)
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(Figure 7). 17 cases showed at least focally myxoid stromal changes while a hyalinized 
background was noted in 10 cases. Scattered mast cells were found throughout the 
lesions, and lymphocytic aggregates, at least focally, were commonly present. Areas 
of hemorrhage or tumor necrosis were not observed.
 Immunohistochemically, 11 out of 22 cases tested expressed CD34 (Figure 8); one 
of them was only focally positive. α-smooth muscle actin was focally detected in 9 
out of 22 cases tested (40,9%), and epithelial membrane antigen (EMA) in two out of 
six cases. CD99 was positive in two out of four cases. The remaining antibodies 
(desmin, h-caldesmon, S-100 protein, pancytokeratin, CD31) were negative in all 
cases tested. 
 Seven cases analysed by FISH exhibited a monoallelic deletion of the RB1 in a 
considerable number of counted nuclei (Table 3, Figure 9).
Figure 7   Prominent pseudovascular structures were found in 3 cases, as seen in 
Case 10
Figure 8   Strong CD34 positivity accented in Case 3 the multinodular architecture Figure 9   FISH analysis: monoallelic loss of RB1 was found in all 7 cases tested.  
A negative control with both alleles of RB1 is seen on the right
Table 3  Results of RB1 FISH Analyses
Case 9 Deletion in 33 out of 63 nuclei counted
Case 10 Deletion in 16 out of 49 nuclei counted
Case 15 Deletion in 27 out of 52 nuclei counted
Case 16 Deletion in 24 out of 51 nuclei counted
Case 17 Deletion in 19 out of 56 nuclei counted
Case 19 Deletion in 42 out of 56 nuclei counted
Case 25 Deletion in 26 out of 54 nuclei counted
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 The follow-up (6 month) was as in all other cases of our series unremarkable. This 
finding is in agreement with the reported cases.6,8 Therefore, the biologic significance 
of atypia and sarcomatous transformation remains uncertain.8
 One of the differential diagnoses of cellular angiofibroma is solitary fibrous tumor 
which can also include fat and shows almost always positivity for CD34.20 Hemangio-
pericytoma-like vessels were observed in a subset of cellular angiofibroma 2,3,18 and 
we also could find this vascular pattern in three cases. We considered this alternative 
possibility in one of our cases occurring in the upper eyelid and showing strong 
positivity for CD34. The cells were arranged in a myxoid matrix, as also described for 
solitary fibrous tumor.21 However, our case consisted of evenly distributed spindle 
cell lipoma like cells. A prominent vasculature, typically seen in cellular angiofibroma, 
with partly hyalinized vessels was existent, but hemangiopericytoma-like vessels 
were not present in this case.  
 Whereas losses on chromosome 13q have been detected in solitary fibrous tumor, 
cytogenetic analyses to date have not found any consistent genetic abnormalities.22-24
 Superficial myofibroblastoma of the lower female genital tract probably belongs 
to the morphologic spectrum of vulvovaginal stromal polyps. Variegated patterns are 
described including myxoid, lacelike, sieve-like, fascicular or storiform. The collagenous 
stroma sometimes contains thick collagen bundles.25-27 Desmin is a discriminating 
marker as cellular angiofibromas are negative for this antibody.1-3,18,25-27
 Angiomyofibroblastoma could also potentially be confused with cellular angio -
fibroma, because of its localization in the genital region.28-31 It is composed of more 
epithelioid and often plasmocytoid cells arranged in cords and nests preferentially 
around vessels. Mast cells can be abundant. The tumor cells express desmin and 
rarely CD34 and smooth muscle actin.28-32 Morphologically malignant cases resembling 
leiomyosarcoma or undifferentiated sarcoma have been reported. As described in 
cellular angiofibromas, none of these has metastasized to date, and one recurred 
2 years later.33,34
 Deep (“aggressive”) angiomyxoma involves the pelvic region, tends to be quite 
large and displays an infiltrative growth with entrapment of mucosal glands, fat, 
muscle and nerves. The prominent vascular component shows hyalinization or 
hypertrophy. Myoid bundles, mostly adjacent to medium sized vessels, are a typical 
finding. There is a variable positivity for desmin, smooth muscle actin and CD34.28,31,35-38
 Superficial angiomyxoma occurs among others in the genital region and possesses 
prominent myxoid stroma with delicate thin-walled vessels. Inflammatory cells, 
particularly neutrophils, are a diagnostic clue. Entrapment of an epithelial component 
is present in a third of the cases. This lesion may be positive for CD34.28,39,40
 Juxtaarticular myxoma, most frequently located on the knee, arises particularly 
in men. This lesion shows a striking accumulation of mucinous material with poor 
cellularity.41 Our cases located on the knee showed mucoid degeneration but they 
Discussion 
Cellular angiofibromas, most commonly described in the genital region of both genders, 
are rare benign mesenchymal neoplasms characterised by a bland spindle cell component 
and numerous small- to medium-sized vessels with mural hyalinization. Typically, there is 
a wispy collagenous, occasionally myxoid stroma. A mature adipocytic component is 
variably seen.1-3
 A morphological overlap with spindle cell lipoma and mammary-type myofibro-
blastoma has been amply described. Whereas a more fascicular pattern has been 
attributed to the mammary-type myofibroblastoma, a more haphazard arrangement 
was observed in the other two neoplasms. On the other hand, ropey collagen is a 
characteristic finding in spindle cell lipoma and mammary-type myofibroblastoma. 
The striking hyalinized vessels are distinctive for cellular angiofibroma.1-3,9-11,17,18 
 There are few reported lesions in extragenital localisations, including retro-
peritoneum, pelvic and lumbal region, anus, urethra, trunk, and oral mucosa.3-7 
Our files contained three extragenital tumors located on the knee (n=2) and upper 
eyelid (n=1). These cases also had classical histological features with obvious hyalinized 
vessels and, at least focally, finely collagenous background.
 Mature adipocytes were found in approximately one third and pseudovascular 
structures were present in three of our cases. These findings are in line with earlier 
descriptions.2,3,19
 Immunohistochemically, expression of CD34 was seen in 50% of the cases tested, 
whereas none of our cases analyzed showed an expression of desmin in accordance 
with reports of others.2,3 In comparison, spindle cell lipoma and mammary type 
 myofibroblastoma are consistent positive for CD34 and the latter shows always 
coexpression of desmin.11
 A genetic link between cellular angiofibroma, mammary-type myofibroblastoma 
and spindle cell lipoma was demonstrated in some cases, all showing a typical loss of 
genetic material from the 13q14 region, as indicated by monoallelic deletion of RB1 
and FOXO1.14,16 Herein we proved by FISH the heterozygote loss of RB1 in all examined 
cases (n=7), thus confirming this relationship.
 Hitherto, there are few reported cases of cellular angiofibroma with atypia or 
sarcomatous features. One case was located in the subcutis of the iliacal region and 
the others were localized in the vulva. Two cases contained areas of a pleomorphic 
liposarcoma and three of an atypical lipomatous tumor.3,8 Our transformed case 
was akin to a malignant solitary fibrous tumor with pleomorphic spindle cells as 
characterized by Kandil et al6 and Chen and Fletcher8 and occurred also in the vulva. 
McCluggage et al18 depicted in their series one case of the vulva with marked nuclear 
pleomorphism resembling symplastic change in uterine leiomyoma.
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were more cellular with typical features of cellular angiofibroma. In one of them we 
could demonstrate loss of RB1 (case 9).
 Benign nerve sheath tumors, as schwannoma and neurofibroma, contain more 
wavy and buckled nuclei. Discriminating S100 positivity is never described in cellular 
angiofibroma.2,3 We confirmed this finding in our study group. 
 Expression of EMA, as seen in two out of six of our cases, could lead to the 
differential diagnosis of soft tissue perineurioma. The storiform, fascicular and/or 
whorled growth pattern of spindle cells with delicate processes are characteristic for 
this lesion.42 
 In summary, we could extend the clinicopathological features of cellular angio- 
fibroma including a morphologically sarcomatous transformed variant and further 
extragenital localisations. Moreover, the confirmation of the genetic relationship 
between cellular angiofibroma, mammary-type myofibroblastoma and spindle cell 
lipoma suggests that these tumors are a spectrum of one entity. RB1 FISH analysis 
could be an ancillary tool for supporting these diagnoses, but the specificity is 
uncertain by now.
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CHAPTER 8 DESMOID-TYPE FIBROMATOSIS OF THE HEAD/NECK IN THE PEDIATRIC POPULATION
Introduction
Desmoid-type fibromatosis (desmoid) is a locally aggressive (myo)fibroblastic lesion 
with sporadic or rarely, familial occurrence. Although more frequent in (young) adults, 
it represents one of the more common fibrous tumors in children and adolescents.1 
In this age group, the head and neck region is more often involved when compared 
to adults.1-5 
 Desmoplastic fibroma, supposed to be the morphological bone counterpart, 
arise also in the head and neck region of young patients, mainly within the mandible.6-8
 Activating CTNNB1 gene mutations (location 3p21) are found in about 85% of all 
sporadic desmoids, with p.T41A (threonine to alanine), p.S45F (serine to phenylalanine) 
and p.S45P (serine to proline) being the most frequent ones. This is similar for children 
and adults.9-13 In contrast, analyses in desmoplastic fibroma have failed to show these 
genetic abnormalities.6,9
 In FAP patients (Gardner Syndrome), desmoid develops on the base of inactivating 
APC gene mutations, which however also may occur in sporadic cases.1,3,14-16 
 β-catenin and APC are part of the Wnt signaling pathway, and mutations in either 
gene cause stabilization of β-catenin with nuclear translocation and binding to the 
T-cell factor/lymphoid enhancer factors (TCF/LEF) family of transcription factors. 
Subsequently, target genes involved in tumor biology of desmoid become activated.9,12-15 
Moreover, it was demonstrated that desmoid is derived from mesenchymal stem cells 
and β-catenin supports tumorigenesis by maintaining mesenchymal progenitor cells.17
 Nuclear accumulation of β-catenin is detectable by immunohistochemistry, a 
useful diagnostic adjunct, but limitations have been acknowledged.9,10,12,15,18-20
 In this study, we report the clinicopathological and genetic data of seven pediatric 
patients with lesions in the head and neck region including 2 intraosseous neoplasms 
of the mandible. 
Material and Methods
The cases were retrieved from the authors’ (referral) files. Clinical details and follow-up 
were obtained from the referring physicians. In all cases the tissue was fixed in 4% 
buffered formalin, routinely processed including decalcification, if needed, and 
embedded in paraffin; 2-4 µm thick sections were stained with hematoxylin and eosin 
and immunohistochemically by the labelled Streptavidin Biotin technique using a 
commercially available antibody against β-catenin (BD Biosciences, clone 14, dilution 
1:100). Appropriate positive and negative controls were used throughout.
 DNA was isolated from formalin-fixed, paraffin-embedded material (without 
 decalcification) by proteinase K digestion and the crude DNA extract was used in a 
Abstract
Desmoid-type fibromatosis (desmoids) is a locally aggressive (myo)fibroblastic lesion. 
It represents one of the more common fibrous tumors in children and adolescents. 
The head and neck region is more often involved when compared to adults. 
 We investigated the clinicopathological and genetic characteristics of seven pediatric 
desmoids at this anatomic site, including  two cases of desmoplastic fibroma, located 
in the mandible. There were two females and five males with an age range from 1.5 
– 8 years. Sites of the soft tissue lesions were sinonasal (n=4), and paramandibular 
(n=1). All cases showed typical morphology and nuclear β-catenin expression. CTNNB1 
gene sequencing, successfully performed in five cases, revealed mutations in three 
cases with one p.T41A (bone lesion), one p.S37A and one novel mutation, p.D32V 
(sinonasal soft tissue lesion each). Seven patients were treated by excision with 
positive margins in five cases. Follow-up, available for six patients (median, 4 years) 
showed no evidence of disease in four cases, slow progression in one case and 
recurrence with stable disease in the last case. 
 Our study provides evidence of genetic similarities in desmoid and desmoplastic 
fibroma. Additionally, we expanded the spectrum of mutations in CTNNB1 with one 
for desmoid novel mutation. 
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 Six patients were treated by excision. Microscopically positive margins were 
documented in five cases. Case 7 was completely resected with negative margins. 
Follow-up, available for six patients (median, 4 years) showed no evidence of disease 
in four cases, slow progression in one case and recurrence with stable disease in the 
final case.
 Case 3 was reported earlier as an odontogenic myxoma, afterwards considered 
to be a wrong diagnosis.21
 Grossly, the tumors ranged in size from 3 to 7 cm and had infiltrative edges. 
Secondary bone involvement in the soft tissue lesions and extension into soft tissue 
in one bone tumor was obvious. Five tumors appeared mainly myxoid. In areas, they 
were firm and white with a coarse trabeculated cut surface. Two cases had only the 
latter appearance.  
 Histologically, all lesions infiltrated adjacent structures and were composed of 
ill-defined long fascicles of uniform (myo) fibroblasts (Figure 2) with slender tapering 
or stellate-shaped nuclei with a vesicular chromatin. Mitoses were found in two cases 
(max. 2/10 HPF). Five lesions had an extensive myxoid background and the cells were 
more loosely arranged (Figure 3). In areas, there were coarse keloid-like collagen 
standard PCR. The hotspot region for CTNNB1 was amplified using primers: 5’-ATGGC-
CATGGAACCAGACAGA-3’ and 5’-GCTACTTGTTCTTGAGTGAAGGACTG-3’. The region 
most frequently mutated in APC (NM_000038.5: amino acids 1200-1580) was 
amplified using the following primer pairs: 1) 5’-CAGATATTCCTTCATCACAGAAAC-3’ 
and 5’-GGAGTATCTTCTACACAATAAGTCTG-3’, 2) 5’-GCCACTTGCAAAGTTTCTTC-3’ and 
5’-TCACAGGATCTTCAGCTGACCT-3’, 3) 5’-TCAGACGACACAGGAAGCAGAT-3’ and 
5’-TTTTGGGTGTCTGAGCACCACT-3’, 4) 5’-AGCCAGGCACAAAGCTGTTGAA-3’ and 
5’-TGTCCAGGGCTATCTGGAAGATCA-3’, 5) 5’-ACCATGCAGTGGAATGGTAAGTGG-3’ and 
5’-TGGAAGAACCTGGACCCTCTGAA-3’, 6) 5’-TGGACCTAAGCAAGCTGCAGTA-3’ and 
5’-CTGCTCTGATTCTGTTTCATTCCCATTGT-3’, 7) 5’-TCTGAGCCTCGATGAGCCATTT-3’ and 
5’-ACGTGATGACTTTGTTGGCATGG-3’. All PCR products were analyzed by fluorescent 
di-deoxysequencing.
Results
Clinical data are presented in Table 1. 
 Patients were two females and five males with an age range from 1.5 – 8 years 
(mean, 3 years; median, 2.5 years). The lesions were situated in the sinonasal (n=4) 
(Figure 1) and paramandibular (n=1) soft tissue. Secondary bone involvement was 
shown in all cases. Two tumors were located intraosseously in the mandible (Cases 6 
and 7). In Case 7, extension into adjacent soft tissue was evident. Secondary bone 
involvement by a primarly soft tissue lesion was excluded on clinical and radiological 
grounds.
Table 1  Clinical Data
Case Age/  
sex
 Site Size  
(cm)
Treatment Follow-up
1 1.5 y/m sinonasal 3.1 excision, R1 3 y; rec/stable
2 1.5 y/m sinonasal 4.5 excision, R1 3 y; NED
3 1.5 y/m sinonasal 4 excision, R1 7 y; NED
4 2.5 y/f sinonasal 5.3 excision, R1 5 y; NED
5 2.5y/m paramandibular 7 excision, R0 NA; recurrence
6 8 y/f mandible (osseous) 6 excision, R1 3 y; slow progression
7 3 y/m mandible (osseous, soft 
tissue involvement)
3 resection, R0 13 y; NED
Y, years; f, female; m, male; NED, no evidence of disease; NA, information not available
Figure 1   MRI depicts a relatively circumscribed sinonasal mass (Case 1)
8116 117
CHAPTER 8 DESMOID-TYPE FIBROMATOSIS OF THE HEAD/NECK IN THE PEDIATRIC POPULATION
bundles (Figure 4). The background was mainly collageneous in one soft tissue and 
one bone lesion (Cases 5 and 7) (Figure 5). Prominent vascularisation with parallel 
alignment to the fascicles was a feature in all cases (Figure 2). Some vessels were thick 
walled and a perivascular edema was present (Figure 6). Hemorrhage was obvious in 
three of the myxoid lesions (Figure 7).
 Immunohistochemically, nuclear β-catenin was observed in all samples in at least 
10% of the tumor cells (Table 2, Figure 8).
 CTNNB1 gene sequencing showed mutations in three of five cases with one 
p.T41A (Case 6, mandibular lesion) (Figure 9), one p.S37A, and one p.D32V (Case 4, 
Figure 10) with the latter representing a hitherto undescribed mutation in desmoids. 
APC mutations were not found in the mutational cluster region in two cases with 
CTNNB1 wild type. No data was obtained from the remaining two samples due to 
poor DNA quality (Table 2).
Figure 2   Low magnification shows a fascicular arrangement of uniform (myo)
fibroblasts. Note the typical vascular pattern and the myxoid background
Figure 3   Loosely arranged spindle cells due to a myxoid background were seen in 
almost all lesions
Figure 4   Thick collagen bundles were common
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Figure 5   Desmoplastic fibroma with classical morphology. Preexistent bone is seen 
below
Figure 7   Erytrocyte extravasation was observed in some of the cases with myxoid 
background
Figure 6   Typical features of a desmoid with thick walled vessels and a perivascular 
edema
Figure 8   β-catenin was accumulated in the nuclei of all samples
8120 121
CHAPTER 8 DESMOID-TYPE FIBROMATOSIS OF THE HEAD/NECK IN THE PEDIATRIC POPULATION
Discussion
Herein we present seven cases of desmoid of the head and neck in pediatric patients 
and show genetic similarities of soft tissue and bone lesions (desmoplastic fibromas). 
Case 6, located in the mandible bone (without soft tissue extension), harbored a 
p.T41A mutation, which is a classical hot spot mutation in soft tissue tumors. To our 
knowledge, this is the first case providing genetic evidence of the morphologically 
suggested relationship of desmoid and desmoplastic fibroma.6,9 Our results disagree 
with those of Hauben et al.6 Possibly, this might be due to decalcification hampering 
mutational analysis because of a higher degree of DNA fragmentation. As we were 
able to use undecalcified tissue, a better DNA quality may explain the discrepancy.
 Genetic similarities between desmoids and desmoplastic fibromas were earlier 
demonstrated with occurrence of trisomies 8 and 20. However, these aberrations 
were also reported in a variety of other fibrous and fibro-osseous lesions and 
therefore are not specific.22 Recently, Trombetta et al. (2012) described an exchange 
between chromosome arms 11q and 19p in a case of desmoplastic fibroma. Whether 
this is a specific and consistent abnormality remains yet unknown.23
 In two sinonasal soft tissue lesions, we found two point mutations in codon 32 
and 37 (exon 3) of CTNNB1 – p.D32V (aspartic acid to valine) and p.S37A (serine to 
alanine). P.D32V has not yet been reported in desmoids while p.S37A was described in 
a single case in a recently published large series.13 Other rare mutations, p.I35S and 
p.T41I, have been detected earlier in cases of head and neck desmoids possibly 
suggesting that heterogeneous mutations are associated with this site.24,25
 In contrast, a more homogeneous mutation pattern has been demonstrated in 
other localizations with p.S45F overrepresentation in tumors of the extremities and a 
Figure 9   A classical hot spot mutation of desmoids was found in a desmoplastic 
fibroma of the mandible (Case 6)
Figure 10   Novel mutation encountered in desmoid Case 4
Table 2  Immunohistochemisty and mutational analysis
Case β-catenin (IHC) CTNNB1 (exon 3)
1 nuclear +/cp + c.109T>G (p.S37A) 
2 nuclear +/cp + wild type 
3 nuclear +/cp + wild type 
4 nuclear +/cp + c.95A>T (p.D32V) 
5 nuclear +/cp + not available
6 nuclear +/cp + c.121A>G (p.T41A) 
7 nuclear +/cp + not available
Cp, cytoplasmic
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seems to be different with a complex translocation described in a single case.8
 Malignant peripheral nerve sheath tumor (MPNST) is outside the NF1(neuro-
fibromatosis type 1) -setting less likely. Nuclear atypia can be mild in MPNST and 
desmoids are known for traces of S-100 protein positivity which can be confused with 
morphologically low grade MPNST.39 Nuclear β-catenin labeling has been reported.40
 Myofibroma, a relatively common tumor in childhood, has a predilection for the 
head and neck, and bone involvement has been reported. The biphasic appearance of 
myoid nodules with a distinctive myxohyaline matrix and hemangiopericytoma-like 
intervening areas denotes this lesion.1 Moreover, there is no nuclear β-catenin 
expression.18 
 Leiomyosarcoma rarely occurs in children although the head and neck region can 
be involved.41 Low-grade lesions may be confused with desmoids probably based on 
the rare expression of desmin in addition to SMA.8 H-caldesmon demonstrates 
smooth muscle differentiation and is not expressed in myofibroblastic lesions42 and 
nuclear β-catenin accumulation has not been observed in leiomyosarcomas.18
 Extrapulmonary inflammatory myofibroblastic tumor (IMT) is a plausible 
consideration when fascicles and a prominent collagenous background are present43 
but the prominent inflammatory reaction throughout the lesion is a distinguishing 
mark.39 ALK expression and rearrangements (2p23) are reported in 50% - 70% of the 
cases.44-46 Furthermore, ALK staining is negative in desmoids47 and, there is no 
nuclear β-catenin expression in IMT.19
 Infantile fibrosarcoma almost exclusively occurs in the first year of life and the 
head and neck is a possible site. This lesion, composed of fascicles or sheets of more 
primitive myofibroblasts with enlarged nuclei, often shows a high mitotic activity. The 
immunophenotype is variable and both SMA and desmin can be positive. ETV6-NTRK3 
fusion is the molecular key to the diagnosis.8,39,48
 Also a hypertrophic scar can mimic desmoid, and sometimes, this is an important 
differential diagnosis, especially in surgically treated desmoid patients. However, a 
hypertrophic scar lacks the fascicular and vascular pattern of desmoids, and nuclear 
β-catenin staining is also absent.1,10
 Regarding treatment, one of the main problems in managing desmoids is their 
high propensity to recur after initial treatment, but this is unpredictable and stable 
disease and even regression are also possible outcomes.
 Therefore, surgery as the mainstay is under debate and a wait-and-see policy as 
initial strategy in a none-life threatening site and in the absence of marked progression 
is being adopted. Furthermore, function-sparing intervention should be preferred to 
aggressive surgery aiming at negative margins.2,4,16,49
 Whether age has a prognostic impact is controversial.4,16,50 Two studies of the 
pediatric population showed that younger age (<10 years) is a favorable prognostic 
factor.4,50
prevalence of p.T41A in mesenteric lesions.10,12,13,20,26 Additional novel point mutations in 
codon 32, 33, 34, and 45 were detected in only about 3% of desmoids.13,20 In this context, 
Huss et al stressed the impact of chosen methods to find unexpected mutations.20
 None of our patients showed a mutation in the APC gene nor were they known to bear 
familial adenomatous polyposis (FAP)-syndrome. This is not surprising when we consider 
that FAP related desmoids have a prevalence of around 70% for the abdominal 
site.27,28 Also in sporadic desmoids with APC mutations, the abdomen is a predilection 
site.29,30 A genotype-phenotype correlation has been reported in FAP patients as 
well with mainly different mutations in extremities and the abdominal site.28 
 (Myo) fibroblastic lesions entering the differential diagnosis of desmoids in the 
pediatric population at this anatomic site are cranial/nodular fasciitis, low-grade 
fibro myxosarcoma, low-grade myofibroblastic sarcoma, lipofibromatosis, malignant 
peripheral nerve sheath tumor, myofibroma, leiomyosarcoma, inflammatory myo-
fibroblastic tumor, and hypertrophic scar.
 Cranial/nodular fasciitis is an important alternative diagnostic possibility, especially 
in cases with loosely arranged myxoid areas. Shorter fascicles, intermingled inflammatory 
cells and erythrocyte extravasation are characteristic for this lesion.1 Erythrocyte 
extravasation can also be present in desmoids as we found in three of our cases. But 
the more thick-walled vessels and degenerated skeletal muscle at the edge of 
desmoids are discriminating.1 Moreover, nuclear expression of β-catenin has not 
been attributed to nodular fasciitis.19 When taking genetics into account, USP6 
rearrangement was found in all investigated nodular/cranial fasciitis cases suggesting 
that USP6-FISH is a useful diagnostic adjunct in difficult cases.32 In contrast, cranial 
fasciitis cases with mutations in CTNNB1 and APC, probably represented examples of 
desmoid, as illustrated and discussed by the authors.25 
 Another differential diagnosis is that of low-grade fibromyxoid sarcoma (LGFMS).33 
LGFMS also affects children and may occur in the head and neck region34,35 and a 
more fascicular pattern of the bland looking fibroblasts can resemble desmoid.34 
As recently demonstrated, MUC4 is a specific immunohistochemical marker for this 
tumor and FUS-CREB3L2/FUS-CREB3L1 fusions are the genetic findings in the majority of 
cases.35-37 Regarding nuclear expression of β-catenin, there are discrepant results.9,18 
 Low-grade myofibroblastic sarcoma (LGMS) characterized by fibromatosis-like 
features has a predilection for the head and neck region but children are rarely 
affected. Histologically, the fascicles are more cellular and the myofibroblasts possess 
atypical nuclei with hyperchromasia.8 Presence of nuclear expression of β-catenin 
does not rule out this tumor-type19 but described genetic aberrations are quite 
different from desmoid.8,38
 Lipofibromatosis, a rare tumor in childhood, is reported in the head and neck area 
and shows a fatty component between fibrous streaks. The latter closely resembles 
desmoids, but there is no nuclear reaction for β-catenin and the genetic background 
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 It also seems that lesions in the head and neck have a relative good prognosis 
particularly when treated by surgery2,4,50 and microscopic extension into the margins 
does not impair the result.2,4,16,26 Our study supports these findings. However, when 
vital structures are involved, the risk of morbidity and mortality are high in this 
region.2,49,51 An alternative therapeutic perspective could be small molecule 
inhibitors of the Wnt/ β-catenin signaling.52
 In summary, the head and neck region is a preferential site of desmoids in the 
pediatric population often associated with a good prognosis. Comparable lesions in 
the bone (desmoplastic fibromas) are genetically related as we could demonstrate for 
the first time. Regarding the broad spectrum of differential diagnosis, morphology is 
still the diagnostic cornerstone. Mutational analysis of CTNNB1 can be a confirming 
adjunct in most of the cases since morphologic mimics are negative.13,53 Finally, we 
expanded the spectrum of mutations in this gene by describing one novel and one 
rare mutation outside the regular hot spots as currently listed for this tumor. 
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There has been huge progress in our understanding of soft tissue tumors including 
clinicopathologic characterization of new entities, major revisions of the classifications 
and, most especially, recognition of the molecular genetic basis of many of these lesions, 
yielding not only pathogenetic insights but also a range of valuable new diagnostic 
tools. This has direct practical relevance to surgical pathologists and, consequently, 
for patients and clinicians as well.1
 In this respect, we discuss herein rearrangements and gene fusions in different 
tumor types with the main topic being EWSR1 rearrangement in myoepithelial 
tumors. Additionally, changes of important tumor suppressor genes in epithelioid 
sarcoma and cellular angiofibroma, and mutations in the oncogene CTNNB1, known 
to be involved in the development of desmoid fibromatosis, are debated.
Rearrangements involving EWSR1 (22q12) were first described in Ewing sarcoma. 
However, it has become increasingly clear that EWSR1 is a “promiscuous” gene, with 
rearrangements involving a number of different partner genes identified in a variety 
of clinicopathological distinct soft tissue tumors including soft tissue myoepithelial 
tumors, extraskeletal myxoid chondrosarcoma, desmoplastic small round cell tumor, 
clear cell sarcoma, angiomatoid fibrous histiocytoma, primary pulmonary myxoid 
sarcoma, clear cell sarcoma-like gastrointestinal tumor, and a subset of myxoid 
liposarcomas, and low-grade fibromyxoid sarcomas/sclerosing epithelioid 
fibrosarcomas.2,3 EWSR1 rearrangements have also been identified in non-mesenchy-
mal tumors, hyalinizing clear cell carcinoma of the salivary gland and clear cell 
odontogenic carcinoma.2,4,5 The issue of EWSR1 rearrangement has been further 
explored in chapters 2 to 5. 
 Cutaneous myoepithelial tumors and their soft tissue counterparts represent 
points along a clinicopatholological spectrum that was extended to include 
myoepithelial tumors of the bone and some visceral sites (salivary glands and lung). 
They can be benign or malignant and histomorphological criteria have been proposed 
to define the dignity. The suggested morphological relationship of tumors at the 
mentioned sites was supported by evidence of EWSR1 rearrangement in a subset of 
cases with the same frequency (ca. 50%) in skin, as shown in our study (chapter 2), 
and soft tissue tumors. To date, four different fusion partners were found – POUF5F1, 
PBX1, ZNF444, and ATF1 with the lowest frequency for the latter two genes. 
EWSR1-ATF1 has been detected in one of our soft tissue tumors (chapter 3).
 Hitherto known alternative rearranged genes to EWSR1 are PLAG1 and exceptionally 
FUS.6,7,8 
 Extraskeletal myxoid chondrosarcoma is a malignant tumor of the deep soft 
tissue and a morphologic mimic of myoepithelial tumors. Since EWSR1 rearrangement 
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and validated in our study. While the MKL2 protein is known to be involved in 
chromatin remodeling and transcription, the function of C11orf95 is as yet unknown. 
In conclusion, this recently detected genetic characteristic could be a useful diagnostic 
adjunct in morphological difficult cases to avoid overtreatment. Furthermore, it 
shows the upcoming myriad of fusion genes disclosed by introduction of a variety of 
new molecular detection methods.
 The next chapter, Chapter 7, shows deletion of the tumorsuppressor gene RB1 as 
a recurrent genetic aberration in cellular angiofibroma. This benign tumor, mostly 
occurring in the inguinogenital region of adults is morphologically, immunohisto-
chemically and genetically related to spindle cell lipoma and mammary-type myo-
fibroblastoma. This is supported by the shown loss of RB1. Due to their relationship 
one could argue that these lesions represent a spectrum of one entity with different 
localizations rather than different tumor types. 
 In chapter 8, we characterized desmoid-type fibromatosis occurring in the head 
and neck region of the pediatric population. Head and neck desmoids are dispropor-
tionately common in children and are clinically characterized by a good prognosis 
independent on the result of surgery. Desmoids have a recurrent mutation of CTNNB1 
resulting in nuclear accumulation of beta-catenin that activates the wnt-signaling and 
is, at least in part, responsible for tumorigenesis. From the diagnostic point of view, 
immunohistochemical detection of nuclear accumulation beta-catenin and mutational 
analysis of the corresponding gene can support the diagnosis, even in small biopsies. 
We found in our cohort one novel and one rare mutation in this gene suggesting a 
more heterogeneous mutation pattern in exon 3 of CTNNB1 at this anatomic site. 
Furthermore, one bone lesion, called desmoplastic fibroma, located in the mandibular 
bone, showed a hot spot mutation. Therefore, a morphologically suggested link with 
desmoids was genetically confirmed in our study.  
 The last two chapters show that implementation of genetic characteristics of soft 
tissue (and bone) tumors can influence morphological classifications forming families 
of tumors with the same biologic background.
 All here described molecular changes are consistent and specific findings and 
their detection can be used as ancillary diagnostic tools for pathologists in making a 
proper diagnosis and consequently, helping clinicians in managing treatment for 
patients.
 New insight in pathobiology of the decribed lesions is a step towards tailored 
treatment possibilities especially in sarcomas. The genetic characterization of benign 
lesions helps to simplify classifications when relationships between tumors are 
obvious as we could demonstrate for cellular angiofibromas and desmoid fibromatosis. 
occurs in both entities, the specific rearrangement of NR4A3 in extraskeletal myxoid 
chondrosarcoma is the most reliable discriminating feature (chapter 4). The distinction is 
important because of the different biological behavior. Whereas myoepithelial 
carcinomas (malignant myoepithelial tumors) are often aggressive tumors, especially 
in children, extraskeletal myxoid chondrosarcoma has a prolonged clinical course. 
This can have impact on possible tailored treatment modalities, especially in the 
children population.9 
 Another potential histomorphologic mimic of myoepithelial tumors is the myxoid 
variant of epithelioid sarcoma. The absence of the INI1 protein is a key immunohisto-
chemical finding in epithelioid sarcomas since it is lost in most of the cases (ca. 90%) 
in comparison to benign myoepithelial tumors in which INI1 is retained. This was also 
a finding of our studies (chapter 2, chapter 5).
 In epithelioid sarcoma, underlying aberrations of INI1, a tumor suppressor gene 
located on the long arm of chromosome 22, are only in part elucidated with 
intragenetic changes (deletions and mutations) in a subset of cases. Therefore, 
alternative epigenetic inactivating mechanisms of INI1 are discussed. The loss of the 
INI1 protein has been established as a useful diagnostic marker for this tumor type. 
However, it has to be mentioned that there is overlap with other entities, e.g. 
myoepithelial carcinomas and epithelioid peripheral nerve sheath tumors. The 
genetic background of the latter two entities is still unknown.
 In conclusion, our study provides evidence of a genetic relationship of 
myoepithelial tumors (benign and malignant) at different sites, especially in skin and 
soft tissue, and expands the spectrum of lesions harboring EWSR1 rearrangements. 
The occurrence of EWSR1 rearrangements in only ca. 50% of tumors with different 
fusion partners demonstrate the genetic heterogeneity of these tumors possessing 
also a protean morphological spectrum. Distinction from morphologic mimics as 
extraskeletal myxoid chondrosarcoma and epithelioid sarcoma is important because 
of the different biology and clinical behavior.
 The EWSR1-ATF1 fusion has been detected in different benign and malignant 
entities as clear cell sarcoma, angiomatoid fibrous histiocytoma, and myoepithelioma 
providing arguments that histomorphology and immunohistochemistry are necessary 
to make the correct diagnosis.
 In chapter 6, we reported on the rare entity of chondroid lipomas. These deep- 
seated benign adipose tumors are genetically characterized by a recurrent translocation 
t(11;16)(q13;p13) with the corresponding fusion gene C11orf95-MKL2. The rarity and 
peculiar morphology of this tumor type with a chondromyxoid matrix can cause 
diagnostic confusion with being the most important differential diagnoses extra- 
skeletal myxoid chondrosarcoma and myxoid liposarcoma. Myoepithelial tumors 
enter also the differential diagnosis, as keratin and S100 expression are overlapping 
immunohistochemical features. The fusion gene C11orf95-MKL2 was recently found 
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more targets will be discovered and become applicable in the near future, and this 
will completely alter the therapeutic approach for patients with soft tissue tumors.
Physicians of the future would extend their diagnostic strategy by elucidating the 
exact molecular basis of each patient’s disease and subsequently apply a specifically 
targeted intervention if available. At the heart of this radically different model for 
patient care lies the application of high-throughput genomic technologies in individual 
patients.13 However, the next couple of years, histomorphology will still be the first 
step to characterize a given tumor at least for representativity and to exclude 
unexpected (secondary or reactive) lesions. In addition, different tumor-types share 
identical genetic aberrations (e.g. gene fusions), making histological examination 
essential because of different treatment modalities for different tumor types.
 Because of their knowledge in characterizing tissue, pathologists have to evaluate 
genetic and molecular information with a great appreciation for cellular context 
taking into account the rich interplay between genes, cells and the microenviron-
ment.13 Therefore, they need to interact with molecular geneticists and bioinformati-
cians to provide surgeons and oncologists the information they need for proper 
patient management.
 It is therefore clear that genome-based research on diseased tissues should rely 
on both histopathological and molecular classification systems.13
 The accrual of appropriate tissue samples is one of the greatest challenges in 
genomic research and the development of molecular diagnostic tools. For example, 
many genome-based technologies work best on frozen tissue samples, and a definite 
validation of a particular disease marker or prognostic indicator depends on its 
detection in patients participating in prospective clinical trials. Because pathologists 
are the gateway to high-quality, well characterized tissue specimens, they are in a 
unique position to help push these studies forward.13 Therefore, all soft tissue tumors 
need to be evaluated in a laboratory that provide state of the art biobanking.
 Molecular tools will undoubtedly improve the diagnosis and treatment of illness 
in years to come, but the availability of advanced new technologies is not the same as 
recognizing, understanding and thereby better characterizing a given disease.13
 The goal of personalized medicine is to identify virtually all of the targetable 
genetic and also epigenetic abnormalities (e.g. DNA methylation and histone 
modification) playing a role in the initiation and progression of a patient’s tumor. To 
develop targeted treatment for different cancer types, we also need a more 
sophisticated understanding of tumor-specific antigens and epigenetic changes as 
mentioned above. There likely will be many surprises along the way, and paradigms 
will be discarded. Nevertheless, the goal will always be the same – to treat disease 
and benefit the patient.12 This can be supported and improved by panel discussions 
and national and international networks, especially for rare cancers as are sarcomas. 
Additionally, further research including animal model systems is mandatory.
Future perspectives 
Until now, and as reflected in the current WHO classification of Tumours of Soft Tissue 
and Bone (2013),10 microscopic morphology, supplemented where relevant by 
ancillary techniques (immunohistochemistry and molecular tests) has remained the 
cornerstone of the classification and diagnosis of soft tissue (and bone) tumors. The 
underlying principle is that a tumor is defined by its cell of origin and its state of dif-
ferentiation. It is remarkable that these well-established technologies continue to 
facilitate the clinically useful definition of previously unrecognized tumor-types on a 
regular basis.11
 The classification of tumors nowadays is based on the definition of so-called 
entities. An entitiy is seen as a separate disease and is defined on morphological, 
 immunophenotypical, genetic and clinical features. Ideally, an entity has a specific set 
of criteria and the diagnosis gives clues on prognosis and treatment for the patient 
and the clinician.
 The last couple of years, genetic characterization of soft tissue tumors has become a 
rapidly growing area and findings that are characteristic for individual entities can be 
very useful in understanding their pathobiology, including the detection of pathways 
related to tumorigenesis and in the identification of novel diagnostic markers (e.g. 
gene mutations or amplifications and fusion genes). Methods for this used in daily 
diagnostic practice are PCR and sequencing of the gene products (Sanger method, 
gene scanning and next generation sequencing) and fluorescence in situ hybridization. 
This will radically change the way how soft tissue tumors get diagnosed: not only a 
cell of origine, state of differentiation and disease entity are important for the 
classification of a given tumor, but also the molecular changes will be characterised. 
Already nowadays we see that this lead to targeted treatments that are directed to 
the altered molecular pathway. Consequently, diagnosis and treatment of soft tissue 
tumors enter the area of precision medicine.
 What will be the consequenties of this large scale introduction of genetic techniques 
in soft tissue tumor diagnosis? It can be expected that next-generation sequencing 
will reveal a much higher incidence of tumor-specific aberrations than observed until 
now. These can  directly be used for improved classification of tumors as shown in 
this thesis. Even more important may be the question which of these changes lead to 
altered gene function. To solve this, characterisation of tumor tissue at the RNA and 
protein level will help to distinguish biologically relevant abnormalities from 
alterations that do not have any biological significance. The data need to be combined 
with clinical data in order to provide a clinical relevant picture of the tumor. Some of 
the involved genes and active pathways are targets of drugs already approved for 
therapy of other conditions and it has to be explored whether they represent possible 
treatment strategies for soft tissue tumors as well.12 It can be expected that many 
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Conclusions
In the era of tumor-specific targeted therapies it is essential to correctly identify 
sarcoma types and to exclude mimics from the diagnosis. The rapidly evolving 
molecular approaches are helpful in this process and wil get a more central role. By 
careful correlation of all aspects of a case – clinical, radiological, histologic, immuno-
phenotypic, and molecular – an accurate diagnosis and, consequently, adequate 







Gedurende de afgelopen jaren hebben nieuwe moleculaire technieken ons veel 
inzicht gegeven op het gebied van weke delen tumoren, met name over genetische 
veranderingen met als gevolg de identificatie van nieuwe entiteiten, herziening van 
bestaande classificaties en de implementatie van nieuwe diagnostische methoden.
 Deze inzichten hebben belangrijke gevolgen gehad voor de pathologie van de 
weke delen tumoren, en zeker voor de patiënt en diens behandelaar. 
 Het onderzoek zoals beschreven in dit proefschrift richt zich op een aantal 
aspecten op het gebied van de weke delen pathologie. Als eerste wordt aandacht 
gegeven aan de betekenis van gen herrangschikking in weke delen tumoren, met 
name die, waarbij het EWSR1 gen is betrokken. Volgend onderwerp van aandacht is 
het diagnostisch belang van tumorsuppressor genen in enkele specifieke weke delen 
entiteiten, te weten de epithelioide sarcomen and cellulaire angiofibromen en in het 
laatste hoofdstuk wordt de diagnostische rol van mutaties in het oncogen CTNNB1  in 
het ontstaan van desmoid fibromatose op kinderleeftijd onderzocht en geëvalueerd.
 EWSR1 gen herrangschikkingen zijn voor het eerst in Ewing sarcomen aangetoond. 
Uit meer recent onderzoek is gebleken dat herrangschikkingen van dit gen ook bij het 
ontstaan van andere tumoren een rol spelen. Dit betreft myoepitheliale tumoren, het 
extraskeletale myxoide chondrosarcoom, de desmoplastische small round cell tumor, 
het clear cell sarcoom, de clear cell sarcoma-like gastrointestinale tumor, een subgroep 
binnen de myxoide liposarcomen en het laaggradig fibromyxoid sarcoom/ scleroserende 
epithelioid fibrosarcoom. Ook in de niet tot de groep van weke delen tumoren behorende 
epitheliale tumoren zoals het hyaliniserende clear cell carcinoom van de speekselklier 
en clear cell odontogeen carcinoom zijn EWSR1 gen herrangschikkingen gevonden. 
 In dit proefschrift is vooral aandacht geschonken aan de betekenis van de EWSR1 
gen herrangschikking in de myoepitheliale tumoren en hun belang in het kader van 
de diagnostiek. Hoofdstuk 2 t/m 5 zijn hieraan gewijd. 
 Myoepitheliale tumoren van de huid, weke delen, bot en andere organen lijken 
morfologisch op elkaar. Ze kunnen zowel goedaardig als kwaadaardig zijn en het 
onderscheid tussen beide berust op morfologische criteria. Bovendien zijn deze 
tumoren genetisch verwant omdat ze in ca. 50% EWSR1 herrangschikking vertonen, 
in ieder geval voor de lesies in de weke delen en in de huid. Meerdere fusie genen zijn 
bekend - POUF5F1, PBX1, ZNF444, and ATF1. De laatste twee genen tonen de laagste 
frequentie. EWSR1-ATF1 werd in een van onze weke delen tumoren gevonden 
(hoofdstuk 3). 
 Samenvattend blijkt dat (benigne en maligne) myoepitheliale tumoren in verschillende 
lokalisaties morfologisch en vooral genetisch gerelateerd zijn, met name deze van 
huid en weke delen. De relatief lage percentage EWSR1 geherrangschikte casus (ca. 
50%) laat de genetische heterogeniteit zien die gepaard gaat met morfologische 
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een rol spelen bij het onderscheiden van verschillende entiteiten, maar ook een 
verwantschap tussen ogenschijnlijk verschillende tumorsoorten onthullen.
 Hoofdstuk 8 is gewijd aan de desmoid type fibromatosen in het hoofd hals 
gebied bij kinderen beschreven. Deze locaal aggressieve tumoren komen bij kinderen 
in deze regio vaker voor en tonen meestal een betere prognose vergeleken met 
volwassenen. Zij zijn gekenmerkt door mutaties in het CTNNB1 gen. Uit ons onderzoek 
is gebleken dat desmoiden in het hoofd hals gebied een grotere variatie in mutaties 
in dit gen laten zien dan elders in het lichaam het geval is. Bovendien vonden we een 
nieuwe en een nog slechts éénmaal tevoren beschreven mutatie in deze 
patiëntengroep. Ook zagen we in deze patiëntengroep een desmoplastisch fibroom, 
een lesie morfologisch identiek aan desmoid maar in het bot gelokaliseerd, met een 
voor desmoid klassieke mutatie. Dit ondersteunt de tot op heden controversiële 
opvatting dat het desmoplastisch fibroom in feite een intraossaal desmoid is.
 De laatste twee hoofdstukken laten zien dat implementatie van genetische 
 characteristieken van weke delen tumoren de morfologische classificaties kunnen 
beinfloeden in die zin dat entiteiten worden gevormd waarin morfologisch op elkaar 
lijkende lesies ook een gezamelijke genetische achtergrond hebben.
Blik op de toekomst
Zoals tot op heden ook benoemd in de recente WHO classificatie van weke delen en 
bot is microscopie nog steeds de gouden diagnostiek standaard, soms aangevuld met 
 immunohistochemie en moleculaire analyses. In principe wordt een tumor gedefineerd 
door de veronderstelde cel van herkomst en de graad van differentiatie. Deze robuuste 
en betrouwbare methoden voldoen nog steeds heel goed en leiden nog steeds tot 
het definieren van nieuwe entiteiten.
 De classificatie van tumoren berust op het onderkennen van zogenaamde 
entiteiten. Een entiteit is een ziekte die wordt gedefinieerd door morfologische, 
immuno histochemische, genetische en klinische karakteristieken. Idealiter worden in 
deze genoemde karakteristieken voor elke entiteit specifieke criteria gevonden die 
helpen prognose en behandeling te bepalen wat zowel voor de patiënt als voor de 
clinicus van belang is.
 In de laatste jaren heeft de genetische karakerisering van weke delen tumoren 
grote vlucht genomen. Deze detectie kan behulpzaam zijn bij het begrijpen van de 
pathobiologie van een lesie, daaronder begrepen de bij tumorontwikkeling betrokken 
cellulaire metabole routes alsook identificeren van nieuwe diagnostische markers 
(bv. gen mutaties of amplificaties en fusie genen). In de praktijk methoden zijn PCR en 
sequencing (Sangermethode, gene scanning and next generation sequencing) en 
voorts fluorescentie in situ hybridisatie. Door deze ontwikkelingen zal de diagnostiek 
diversiteit. Het voorkomen van EWSR1 rearrangement ook in deze entiteit expandeerd het 
spectrum van lesies met EWSR1 rearrangement. EWSR1-ATF1 fusie is in verschillende 
benigne en maligne entiteiten aantoonbaar, derhalve is een histopathologische en 
immuunhistochemische beoordeling voor de correcte diagnose noodzakelijk.
 Een maligne weke delen tumor die morfologisch op een myoepitheliale tumor 
kan lijken en bovendien eveneens EWSR1 herrangschikking vertoont is het extra-
skeletale myxoid chondrosarcoom. De EWSR1 fusiepartner in deze tumor is NR4A3. 
De consistente aanwezigheid van dit specifieke fusie gen is derhalve een diagnostisch 
criterium om het onderscheid te maken tussen extraskeletaal myxoid chondrosarcoom 
en myoepitheliale tumoren. De mogelijkheid om dit onderscheid te maken is belangrijk 
vanwege een verschil in hun klinisch gedrag; de maligne myoepitheliale tumoren zijn 
aggressiever (hoofdstuk 4).
 Een andere morfologische nabootser van myoepitheliale tumoren is de myxoide 
variant van het epithelioide sarcoom.  Aanvullende immuunhistochemie met de 
marker INI1 helpt het onderscheid te maken, want het INI1 protein is in epithelioide 
sarcomen consistent afwezig terwijl het in benigne myoepitheliale tumoren wel 
aanwezig is. Dit konden wij bevestigen in onze analyses van de cutane myoepitheliale 
tumoren en de epithelioide sarcomen (hoofdstuk 2 en 5).
 Onderliggende veranderingen in INI1, gelocaliseerd op de lange arm van 
chromosoom 22, zijn deels intragenetisch met deleties en mutaties. Als alternatief 
worden epigenetische inactiverende veranderingen gediscusseerd. Er is gesteld dat 
verlies van het eiwit van INI1 een marker is voor epithelioide sarcomen, maar er moet 
rekening mee worden gehouden dat INI1 ook afwezig is in een deel van andere 
epithelioide tumoren zoals myoepitheliale carcinomen en epithelioide maligne 
perifere zenuwschedetumoren. De genetische achtergrond hiervan is nog onduidelijk.
In hoofdstuk 6 wordt de betekenis van genetische veranderingen voor de diagnostiek 
van chondroide lipomen besproken. Deze tumoren liggen meestal in de diepe weke 
delen en zijn sinds kort bekend met de translocatie t(11;16)(q13;p13), leidend tot het 
ontstaan van het fusiegen C11orf95-MKL2. Deze tumoren kunnen vooral vanwege hun 
chondromyxoide matrix lastig te onderscheiden zijn van maligne weke delen tumoren 
zoals extraskeletaal myxoid chondrosarcoom en myxoid liposarcoom of, vanwege 
een overlappend immunoprofiel met positiviteit voor keratine en S100 verward 
worden met myoepitheliale tumoren.
 Deze studie illustreert de meerwaarde van moleculaire technieken bij het maken 
van het onderscheid tussen morfologisch en immuunhistochemisch overlappende 
entiteiten. Hoofdstuk 7 gaat over de deletie van het tumorsuppressorgen RB1 in 
cellulaire angiofibromen. Deze recurrente aberratie wordt ook gevonden in de 
morfologisch gerelateerde tumoren spoelcellipoom en mammary-type myofibro-
blastoom. Derhalve kan gespeculeerd worden dat deze benigne lesies een spectrum 
van een entiteit representeren. Moleculaire technieken kunnen dus niet alleen 
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dient te worden benadrukt dat een definitieve validatie van  biomarkers is afhankelijk 
van patiënten die participeren in prospectieve klinische studies. Verdere ontwikkeling 
van de moleculaire diagnostiek staat of valt derhalve met het beschikbaar zijn van 
tumormateriaal van goede kwaliteit, afkomstig van adequaat gedocumenteerde en 
gevolgde groepen patiënten. De belangrijke rol van de patholoog in dit verband is al 
eerder genoemd. Hun expertise in weefselkarakterisatie is in deze studies onontbeerlijk. 
 Moleculaire technieken zullen in de toekomst diagnose en behandeling van 
ziekten verbeteren. De beschikbaarheid van moderne technieken is echter niet 
hetzelfde als herkennen en begrijpen van een ziekte met als gevolg betere karakteri-
sering van deze ziekte.
 Voor de ontwikkeling van targeted therapie bij verschillende cancers hebben we 
ook meer kennis nodig betreffende tumor specifieke antigene en epigenetische 
veranderingen. Het doel van individuele geneeskunde is dan ook het opsporen van alle 
genetische en epigenetische (bv. DNA methylering en histon modificatie) veranderingen 
die een rol spelen in tumorontwikkeling of tumorprogressie en behandelbaar zijn. 
Deze innovaties zullen mogelijk onverwachte resultaten opleveren en de huidige 
zienswijze ten aanzien van weke delen tumoren veranderen. Het door al dit onderzoek 
beoogde doel verandert evenwel niet: optimale behandeling van de ziekte en 
bevorderen van het welzijn van de patiënt.
Conclusie
Vanwege de huidige beschikbaarheid van tumorspecifieke behandelopties van een 
tumor is het nu nog meer dan voorheen belangrijk de juiste diagnose te stellen. 
Moleculaire diagnostiek speelt hierbij in toenemende mate een essentiële rol. 
 Om te komen tot deze juiste diagnose en een optimale behandeling is het belangrijk 
om zowel de klinische als de radiologische, histologische en moleculair biologische 
aspecten in de overwegingen te betrekken. 
op het gebied van weke delen tumoren veranderen. Op de voorgrond staat dan de 
genetische karakterisering in plaats van het bepalen van de tumorentiteit aan de 
hand van cel van origine en graad van differentiatie. Dit verschaft de informatie die 
noodzakelijk is om met doelgerichte therapie in te grijpen op het afwijkende 
metabolisme van de tumorcel, de zogenaamde “targeted treatment”. 
 Wat zijn de consequenties van dit palet aan genetische technieken  in de diagnostiek 
van weke delen tumoren? Het is te verwachten dat next generation sequencing een 
hogere incidentie van specifieke genetische afwijkingen per tumor of entiteit toont 
dan wat tot nu toe is gevonden. Daardoor kan de tumorclassificatie worden verbeterd, 
zoals ook in dit proefschrift is aangetoond. Nog belangrijker is de vraag welke 
genetische veranderingen leiden tot veranderde gen functie en zijn derhalve relevant 
voor de tumorgroei? Om deze vraag te beantwoorden is weefselonderzoek op RNA 
niveau en eiwit niveau noodzakelijk. De uit derglijk onderzoek verkregen data zullen 
worden gecorreleerd aan de klinische gegevens om een eventuele relatie met klinisch 
beloop te achterhalen. Op deze wijze zijn al diverse genen en metabole routes 
gevonden als aangrijpingspunt voor doelgerichte behandeling en reeds goedgekeurd 
voor de therapie van andere tumoren maar of deze ook van belang zijn voor de 
behandeling van sarcomen, is nog niet voldoende onderzocht. Bovendien is het 
redelijk te veronderstellen dat er in de toekomst meer genetische veranderingen met 
therapeutisch belang worden gevonden waardoor de behandeling van weke delen 
tumoren en met name van de sarcomen zal veranderen.
 In de toekomst zal de diagnostische aanpak worden uitgebreid door het in kart 
brengen van de moleculaire basis van de ziektes met als gevolg doelgerichte 
interventie. Centraal in dit radicaal veranderde model van patiëntenzorg staat de 
toepassing van genomische technologiën waarmee in korte tijd grote aantallen 
gegevens kunnen worden verkregen. Wat de eerstkomende jaren niet zal veranderen 
is het belang van de histomorphologie omdat weefselkarakterisatie onmisbaar blijft 
voor het vaststellen van representativiteit van het onderzochte materiaal en om 
onverwachte (secundaire of reactieve) lesies uit te sluiten. Bovendien kunnen in 
verschillende tumoren identieke genetische afwijkingen voorkomen, wat histologische 
beoordeling van de lesies voor therapiekeuze essentieel maakt.
 Pathologen hebben een belangrijke functie in deze weefselanalyse. Zij zijn ervoor 
verantwoordelijk genetische en moleculaire informaties in de morfologische context 
te plaatsen waarbij ook kennis van de interacties van cellen, genen en micromilieu 
niet gemist kan worden. Om de clinici de voor een goed beleid noodzakelijke 
informatie te geven is een goede samenwerking van de pathologen met moleculaire 
genetici en bioinformatici nodig. Uit bovenstaande overwegingen is af te leiden dat 
onderzoek van het genoom essentieel is in het verkrijgen van een tumorclassificatie 
die niet alleen op morfologische maar ook op moleculaire data is gebaseerd. De be-
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